

A. **DATE: June 2009**

A. **BIOGRAPHIC INFORMATION**

Name: FELIX ALEXANDER RATJEN

Address – Division of Respiratory Medicine  
Business: The Hospital for Sick Children  
555 University Avenue  
Toronto, Ontario  
M5G 1X8

Address – 6 Tudor Gate  
Residence: Toronto, Ontario  
M2L 1N4

Telephone: (416) 813-6167 (Business)  
(416) 510-8469 (Residence)

Date of Birth: 1960-10-12

Citizenship: German

Languages: English, German

1. Degrees:

MD	1986	Johann Wolfgang Goethe University in Essen, Frankfurt a.M.	Doctor of Medicine
----	------	---	--------------------

MD	1994	Johann Wolfgang Goethe University in Essen, Frankfurt a.M.	Pediatrics
----	------	---	------------

PhD	1996	Johann Wolfgang Goethe University in Essen, Frankfurt a.M.	Habilitation Pediatrics
-----	------	---	-------------------------

Postdoctoral Training:

1987-89	Research Fellowship in Pulmonary Medicine at Children's Hospital, Harvard Medical School, Boston, Massachusetts, sponsored by a grant of Deutsche Forschungsgemeinschaft (DFG).
---------	---

1988-93	Pediatric training, The Children's Hospital, University of Essen, Germany
---------	--

1985	2 months of clinical rotation in pediatric cardiology and respiratory medicine in the Hospital for Sick Children, Toronto, Canada
------	--

Internship and Residency:

1988-93	Pediatric training at the Children's Hospital, University of Essen
---------	--

Licensure:

04.1994	Licensed as specialist in pediatrics, Germany
17.11.1986	State registration as a Medical Doctor, Germany
04.2005	Academic License, College of Physicians & Surgeons of Ontario, Canada
04.2005	Fellow, Royal College of Physicians & Surgeons of Canada

Certification:

8.9.1987	Foreign Medical Graduates Exam of Medical Science“ (FMGEMS).
04.2005	Royal College of Physicians & Surgeons of Canada

2. Employment:

Academic Appointments:

1997	Lecturer, University of Essen, Germany.
6.1998-3.2005	Deputy Chief, Department of Pediatrics, Children’s Hospital, University of Essen
2001-2005	Professor in Paediatrics, University of Essen
04.2005	Division Chief, Respiratory Medicine, Hospital for Sick Children, Toronto.
04.2005	Professor in Pediatrics, University of Toronto, Toronto
06.2006-06.2011	Member, Institute of Medical Science Graduate Faculty, University of Toronto.

Hospital Appointments:

1997-2003	Chief instructor for students at the Children’s Hospital, University of Essen
9.1993	Attending physician at the Children’s Hospital, University of Essen, Germany
04.2005	Senior Scientist, Research Institute, The Hospital for Sick Children, Toronto.
07.2006	Member, Research Advisory Committee, Department of Paediatrics, The Hospital for Sick Children, Toronto
07.2006	Member, CRC Management Committee
07.2007	Associate Staff Physician Department of Paediatrics, Division of Neonatology, Mount Sinai Hospital
2008	Department of Paediatrics Research Day May 2008– Poster judge

2007	Co-Director, Cystic Fibrosis Centre, The Hospital for Sick Children
07.2007	Review Committee (Division Heads Representative), Division of Cardiology 5 year internal review.
02.2008	External Review Committee Division of Clinical and Metabolic Genetics
10.2008	Search Committee - Head of the Division of Clinical and Metabolic Genetics
04.2009	Member, Clinical Research Secretariat, Research Institute

3. Honours:

4. Professional Affiliations and Activities:

2002-05	Secretary of Bronchology Group of the European Respiratory Society
2002-2005	Chief Executive of the Scientific Board of the German CF Foundation (Forschungsgemeinschaft Mukoviszidose)
2005-ongoing	American Thoracic Society – Pediatrics Program Committee
2005-ongoing	Canadian CF Foundation - Clinical Study Network Committee
2006-ongoing	Cystic Fibrosis Foundation (US) Research Development Program Grant Committee
2006-ongoing	North American CF Conference Program Committee
2005-ongoing	Ontario Thoracic Society Grant Committee
19 Sep2007-18 Sep 2010	European Respiratory Society (ERS) – Chair, Cystic Fibrosis Group
2007-2010	European Respiratory Society (ERS) Program Committee
03.2008	University of Toronto Respiratory Research Advisory Committee
05.2008-04.2010	Canadian CF Foundation Research Subcommittee

Ad Hoc Reviewer:

- Allergy
- American Journal of Infection Control
- American Journal of Physiology- Lung Cellular and Molecular Physiology
- American Journal of Respiratory and Critical Care Medicine
- American Journal of Respiratory Cell and Molecular Biology
- Archives of Diseases in Childhood

- Biochimica et Biophysica Acta (BBA - General Subjects)
- Bone Marrow Transplantation
- BMC Pediatrics
- Cellular Microbiology
- Chest
- Clinical Chemistry
- Cochrane CF Group
- Current Drugs
- European Journal of Medical Genetics
- European Journal of Clinical Microbiology & Infectious Diseases
- European Journal of Pediatrics
- European Respiratory Journal
- European Respiratory Society Fellowship
- Expert Review of Anti-infective Therapy
- Expert Review of Pharmacoeconomics and Outcomes
- Future Microbiology/Future Medicine
- Infection
- Investigational Drugs Database
- Journal of Antimicrobial Chemotherapy
- Journal of Cystic Fibrosis
- Journal of Infectious Diseases
- Journal of Pediatric Gastroenterology & Nutrition
- Journal of Pediatrics
- Lancet
- Lung
- Monatsschrift für Kinderheilkunde
- Neuropediatrics
- New England Journal of Medicine
- Pediatrics
- Pediatric Allergy and Immunology
- Pediatric Pulmonology
- Pediatric Research
- Pulmonologie
- Respiratory Medicine
- Respiratory Research
- Thorax
- Vaccine

Associate Editor:

- American Journal of Respiratory and Critical Care Medicine
- Journal of Cystic Fibrosis

Editorial Boards:

- Pediatric Pulmonology
- The Respiratory Report

Grants Reviewed:

- Canadian Cystic Fibrosis Foundation
- CIHR]
- European Respiratory Society
- German CF Foundation

- German Society for Pediatric Pulmonology
- Health Research Board
- INSERM
- Northern Ireland Research Fund
- Swiss CF Foundation
- The Prince Charles Hospital Foundation, Brisbane Australia
- US CF foundation

Committees:

- American Thoracic Society – Assembly on Pediatrics Program Committee
- German Pediatric Society
- German Society for Pediatric Pulmonology
- German CF Foundation
- European Respiratory Society (ERS)
- European Respiratory Society (ERS) – Chair, Cystic Fibrosis Group (19 Sep2007-18 Sep 2010)
- ERS Task Force Groups:
  - Bronchoalveolar lavage in children
  - Interstitial lung disease in children
  - Measurement of nitric oxide in children (ERS/ATS)
  - Non-cellular constituents of bronchoalveolar lavage fluid
  - Paediatric bronchoscopy
- International Society for Chemotherapy

**B. ACADEMIC HISTORY**

1. Research Endeavour

- Nitric oxide and its role in the pathophysiology of pediatric respiratory disease
- Genetic modifiers of disease manifestations in cystic fibrosis
- Early therapy for P. aeruginosa infection in cystic fibrosis
- Airway inflammation in cystic fibrosis
- Non-invasive test to assess airway inflammation
- Infant pulmonary function testing
- Bronchoalveolar lavage and its diagnostic role in pediatric respiratory disease

2. Research Awards

1987-1988	Research grant by Deutsche Forschungsgemeinschaft: Physiologic development of the infantile lung: assessment with age specific lung function tests. €105,000
1993-1995	Research grant by Deutsche Forschungsgemeinschaft: Effect of rapid thoracic compressions on intracerebral pressure in newborn lambs €108,000
1996-1997	Research grant by IFORES: Genotyping of Aspergillus fumigatus species in patients with cystic fibrosis. €52,000

1998-1999	Research grant by IFORES: Genotypic alterations of <i>A. fumigatus</i> in CF patients with allergic bronchopulmonary aspergillosis (ABPA). €48,000
1999-2002	Research grant by the German CF foundation: Bronchoalveolar lavage in the early assessment of anti-inflammatory therapy in CF: a multi-centre study (BEAT). €250,000
1999-2003	Research grant by the German CF foundation: Randomised double blind study of the effect of L-arginine on lung function and bacterial colonization in patients with cystic fibrosis. €22,000
2001-2002	Research grant by IFORES: In vitro effects of cytokine induced NO production on bronchial epithelial cells. €62,000
2001-2003	Research grant by the German CF foundation: Effect of a polymorphism in the angiotensin converting enzyme gene on physical fitness in patients with cystic fibrosis. €23,000
2003-2005	Research grant by IFORES: Prevalence, genomic heterogeneity and clinical significance of human metapneumovirus infection €45,000
04.2005	Research Institute, Hospital for Sick Children Start-up Operating, \$90,000
04.2005	Research Institute, Hospital for Sick Children Start-up Equipment \$80,000
05.2005	Windorfer Prize for outstanding research in CF BEAT Study group €5000
12.2005	Pharmaxis Ltd., & ethica Clinical Research Inc "A Phase IIa Randomized, Open Label, Dose Response Study to Determine the Optimum Dose of Dry Powdered Mannitol Required to Generate Clinical Improvement in Patients with Cystic Fibrosis" Co PI with Dr. M. Solomon \$100,160.06
04.2005- 03.2008	HSC Foundation Sellers Chairholder 2005-06 - \$54,000 2006-07 - \$70,600 2007-08 - \$73,423

06.2006	<p>The Lynne and Arnold Irwin Foundation  Diagnostic Utility of Induced Sputum Using Hypertonic Saline to Evaluate Airway Interaction and Inflammation in Cystic Fibrosis  PI  \$30,000</p>
04.2006- 03.2009	<p>Canadian Cystic Fibrosis Foundation  Characterization of factors and mechanisms affecting physical activity, muscular function and lung health in Cystic Fibrosis  Co-PI with Dr. A. Coates  \$180,000</p> <p>Cystic Fibrosis Foundation Therapeutics Inc.  Multi-Center, Multi National, Randomized, Placebo-Controlled Trial of Azithromycin in Participants with Cystic Fibrosis, 6-18 years old, Culture Negative for <i>Pseudomonas aeruginosa</i> (AZ0004)  (PI Salary support)  \$36,546 USD</p>
10.2006 09.2007 10.2007 09.2008	<p>\$36,546 USD</p>
2006- 2009	<p>Cystic Fibrosis Foundation Therapeutics Inc.  Multi-Center, Multi National, Randomized, Placebo-Controlled Trial of Azithromycin in Participants with Cystic Fibrosis, 6-18 years old, Culture Negative for <i>Pseudomonas aeruginosa</i>  Co-PI  \$5,200,464</p>
10/2006- 09/2011	<p>Canadian Foundation for Innovation  The Hospital for Sick Children Centre for the Study of Complex Childhood Diseases (CSCCD)  (PI – Martin Post)  \$20,571,919</p>
06/2007- 05/2008	<p>The Lynne and Arnold Irwin Foundation  L-arginine in CF  Co-Investigator (P.I. – Dr. H. Grasemann)  \$25,000</p>
04.2007- 03.2010	<p>Canadian Cystic Fibrosis Foundation  Treatment of <i>Aspergillus fumigatus</i> in patients with cystic fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trail  Co-PI with Dr. Shawn Aaron  \$220,800</p>
04.2007- 03-2009	<p>The Physicians Incorporated  Treatment of <i>Aspergillus fumigatus</i> in patients with cystic fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trail  Co-PI with Dr. Shawn Aaron  \$122,000</p>
04.2007- 03.2009	<p>Canadian Cystic Fibrosis Foundation  Effect of increased L-arginine bioavailability on cystic fibrosis lung disease.  Co-Investigator (PI: Dr. H. Grasemann)  \$53,376</p>

04.2007- 03-2009	<p>Canadian Cystic Fibrosis Foundation Breathe Program A randomized-controlled trial of inhaled hypertonic saline (7%) to detect a treatment effect using the lung clearance index in CF patients with normal lung function. PI \$116,831</p>
04.2008- 03.2011	<p>Canadian Cystic Fibrosis Foundation Diagnosing Cystic Fibrosis in Neonates and Adults: Where Do we Draw the Line? \$360,000 Co-Investigator (PI: Durie P)</p>
2007-2008	<p>Vertex Pharmaceuticals, Inc. VX06-770-101: A Phase 2a, Randomized, Double-Blind, Placebo Controlled Study of VX770 in Patients with Cystic Fibrosis having G551D Mutations to Evaluate Safety, Pharmacokinetics and Biomarkers of CFTR Activity Co-Site Investigator (Site PI: P. Durie, Overall PI Dr. F. Accurso)) US\$30,000</p>
11.2007- 10.2008	<p>Hoffman-La-Roche Effect of rhDNase of ventilation in homogeneity in patients with cystic fibrosis PI \$45,000</p>
07.2007- 06.2008	<p>US CF Foundation A Pilot study to Evaluate the Tolerability of inhaled 7% Hypertonic Saline in Infants with Cystic Fibrosis (ISIS-001) \$10,878</p>
10.2007- 09.2008	<p>Bickell Foundation Defining the role of <i>Stenotrophomonas maltophilia</i> in CF patients Co-Investigator (PI: V. Waters, Y.Yau) \$64,975.28</p>
2007-2009	<p>Inspire Inc. Pharmacogenomics of P2Y2 receptor activation PI \$51, 030</p>
2008	<p>Inspire Inc. TIGER-2 (Treating Ions to Generate Epithelial Rehydration) 80 site study in US and Canada - A phase 3, international, multi-centre, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of denufosol tetrasodium inhalation solution in patients with cystic fibrosis lung disease and FEV1= 75% predicted. PI \$42,065</p>

2008-2012	<p>Cystic Fibrosis Foundation Therapeutics Inc.          Inhaled Saline for Infants Study (ISIS-002)          Co Principal Investigator for 18 site study with Dr S. Davies , UNC and M. Rosenfeld, Seattle          US \$ 1,794,674 for first year funding 10/1/07-9/30/08  <i>(continued funding guaranteed for the complete study duration of 4 years through CFF. The study received high scores from the NIH; cofunding is therefore highly likely, final decision 04.08)</i></p>
2008-2009	<p>Gilead Sciences          A Double-Blind, Multicenter, Multinational, Randomized Placebo-Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis Mild Lung Disease and P. aeruginosa (AIR-CF4).          PI          \$39,555</p>
04.2009-03.2011	<p>Canadian Cystic Fibrosis Foundation          Functional relevance of altered l-arginine metabolism in cystic fibrosis lung disease          \$170,000          Co-Investigator (PI: Dr. H. Grasemann)</p>
04.2009-03.2011	<p>Canadian Cystic Fibrosis Foundation          Modulation by sex hormones of inflammation and susceptibility to Pseudomonas aeruginosa in CF airways          \$256,000          Co-Investigator (PI: Dr. N. Sweezey)</p>
04.2009-03.2011	<p>Canadian Cystic Fibrosis Foundation          Defining the role of Stenotrophomonas maltophilia in CF patients          \$240,000          Co-Investigator (PI: Dr. V. Waters)</p>

3. Patents Awarded  
 Nil.

### C. PUBLICATIONS

1. Ratjen F, Wönne R, Posselt HG, Stöver B, Hofmann D, and Bender SW. A double-blind placebo controlled trial with oral ambroxol and n-acetylcysteine for mucolytic treatment in cystic fibrosis. *Eur J Pediatr* 1985; 144: 374-378.
2. Wönne R, Ratjen F, Posselt HG, Stöver B, Bender SW, und Hofmann D. Untersuchungen zur mukolytischen Wirksamkeit von Ambroxol und N-Acetylcystein an Patienten mit Mukoviszidose. *Atemw Lungenkrkh* 1985; 11: 353-354.
3. Ratjen F, Zinman R, Stark AR, Wohl MEB. The effect of changes in lung volume on respiratory system compliance in newborn infants. *J Appl Physiol* 1989; 67: 1192-1197.
4. Ratjen F, Zinman R, Wohl MEB. A new technique to demonstrate flow limitation in partial expiratory flow-volume curves in infancy. *J Appl Physiol* 1989; 67: 1662-1669.
5. Colin AA, Wohl MEB, Mead J, Ratjen FA, Glass G, Stark AR. Transition from dynamically to relaxed end-expiratory volume in human infants. *J Appl Physiol* 1989; 67: 2107-2111.
6. Ratjen FA, Colin A, Stark AR, Mead J, Wohl MEB. Changes of time constants during infancy and early childhood. *J Appl Physiol* 1989; 67(5): 2112-2115.
7. Ratjen FA, and Wiesemann HG. Variability of dynamic compliance measurements in spontaneously breathing and ventilated newborn infants. *Pediatr Pulmonol* 1992; 12: 73-80.
8. Ratjen FA, Schoenfeld B, Wiesemann HG. Pulmonary alveolar microlithiasis and lymphocytic interstitial pneumonitis in a 10 year old girl. *Eur Respir J* 1992; 5: 1283-1285.
9. Ratjen F, Bredendiek M, Brendel M, Meltzer S, Costabel U. Differential cytology of bronchoalveolar lavage fluid in normal children. *Eur Respir J* 1994; 7: 1865-1870.
10. Ratjen F, Bredendiek M, Zheng L, Brendel M, Costabel U. Lymphocyte subsets in bronchoalveolar lavage fluid of children without bronchopulmonary disease. *Am J Respir Crit Care Med* 1995; 152: 174-178.
11. Grasemann H, Wiesemann HG, Ratjen F. Der Voraussagewert der Lungenfunktion auf die 2 Jahresmortalität bei Mukoviszidose. *Pneumologie* 1995; 49: 466-469.
12. Ratjen F, Welker J, Trost A, Spangenberg J, Wiesemann HG. The effect of rapid thoracoabdominal compression on intracranial pressure in newborn lambs. *Pediatr Res* 1995; 38: 664-667.
13. Ratjen F, Rehn B, Costabel U, Bruch J. Age dependency of surfactant phospholipids and surfactant protein A in bronchoalveolar lavage fluid of children without bronchopulmonary disease. *Eur Respir J* 1996; 9: 328-333.
14. Ratjen F, Bruch J. Size correction of bronchoalveolar lavage volume in children. *Pediatr Pulmonol* 1996; 31: 184-188.
15. Ratjen F, Havers W, Costabel U. Differential cytology of bronchoalveolar lavage fluid in immunosuppressed children with pulmonary infiltrates *Arch Dis Child* 1996; 74: 507-511.

16. Ratjen F, Kreuzfelder E. Differences in immunoglobulin and  $\beta$ -2 microglobulin levels between normal children and adults. *Lung* 1996; 174: 383-391.
17. Rath P, Ratjen F, Ansorg R. Genetic diversity among isolates of *aspergillus fumigatus* in patients with cystic fibrosis. *Zentralbl Bakt* 1997; 285: 450-455.
18. Grasemann H, Ioannidis I, de Groot H, Ratjen F. Metabolites of nitric oxide in the lower respiratory tract of children. *Eur J Paediatr* 1997; 156: 575-578.
19. Dörk T, Dworniczak B, Aulehla-Scholz C, Wieczorek D, Böhm I, Mayerova A, Seydewitz HH, Nieschlag E, Meschede D, Horst J, Pander HJ, Sperling H, Ratjen F, Passarge E, Schmidtke J, Stuhmann M. Distinct spectrum of CFTR mutations in congenital absence of vas deferens. *Hum Genet* 1997; 100: 365-377.
20. Braun J, Mehnert A, Dalhoff K, Wießmann KJ, Ratjen F. Different BALF protein composition in normal children and adults. *Respiration* 1997; 64: 350-357.
21. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentrations of exhaled nitric oxide in cystic fibrosis. *Pediatr Pulmonol* 1997; 24: 173-177.
22. Ratjen F. Normal values of bronchoalveolar lavage. *Pediatr Pulmonol* 1997; 25: 101-102.
23. Büscher R, Geiger A, Markgraf G, Reidemeister C, Ratjen F. Einseitige Lungentransplantation bei einem 11-jährigen Patienten mit zystischer Fibrose. *Monatsschr Kinderheilkd* 1997; 145: 353-356.
24. Büscher R, Schaper J, Müller KM, Ratjen F. Pulmonale Manifestation einer Sarkoidose im Kleinkindesalter. *Monatsschr Kinderheilkd* 1997; 145: 802-805.
25. Piotrowski JA, Splittgerber FH, Donovan TJ, Ratjen F, Zerkowski HR. Single-lung transplantation in a patient with cystic fibrosis and asymmetric thorax. *Ann Thorac Surg* 1997; 64: 1456-1459.
26. Ratjen F, Costabel U. Die bronchoalveoläre Lavage im Kindesalter: Technische Aspekte und Referenzwerte. *Pneumologie* 1997; 51: 93-98.
27. Ratjen F. Don't forget the size of the bronchoscope. *Pediatr Pulmonol* 1997; 32: 330-331.
28. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H. A double blind randomised placebo controlled study of inhaled tobramycin in cystic fibrosis patients colonized with *Pseudomonas aeruginosa*. *Pediatr Pulmonol* 1998; 25: 88-92.
29. Grasemann H, Ioannidis I, Tomkiewicz RP, de Groot H, Rubin BK, Ratjen F. Nitrate oxide metabolites in cystic fibrosis lung disease. *Arch Dis Child* 1998; 78: 49-53.
30. Ratjen F, Grasemann H, Wolstein R, Wiesemann HG. Isovolum pressure/flow curves of rapid thoracoabdominal compressions in healthy infants. *Pediatr Pulmonol* 1998; 26: 197-203.
31. Grasemann H, Gaertig SS, Wiesemann HG, Teschler H, Konietzko N, Ratjen F. Effect of L-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. *Eur Respir J* 1999; 13: 114-118.

32. Knauer S, Ratjen F. Lipid-laden macrophages in bronchoalveolar lavage fluid as a marker for pulmonary aspiration. *Pediatr Pulmonol* 1999; 27: 419-422.
33. Ratjen F, Havers W, Braun J. Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia. *Thorax* 1999; 54: 432-436.
34. Ratjen F, Gaertig S, Wiesemann HG, Grasemann H. The effect of inhaled nitric oxide on pulmonary function in patients with cystic fibrosis. *Respir Med* 1999; 93: 579-583.
35. Grasemann H, Gaston B, Fang K, Paul K, Ratjen F. Decreased levels of nitrosothiols in the lower airways of cystic fibrosis patients with normal pulmonary function. *J Pediatr* 1999; 135: 770-772.
36. Fischer-Knauer S, Schaper J, Jansen T, Ratjen F. Tuberculoma of the pons in a 12-year-old boy. *Pediatric Neurology* 1999; 20: 57-59.
37. Midulla F, Ratjen F. Report of the European Task Force for non-cellular components of bronchoalveolar lavage: Special considerations in children. *Eur Respir Rev* 1999; 66: 38-42.
38. Grasemann H, Ratjen F. Cystic fibrosis lung disease: The role of nitric oxide. *Pediatr Pulmonol* 1999; 28: 442-448.
39. Ratjen F, Tümmler B. Comparison of the in vitro and in vivo response to inhaled DNase in patients with cystic fibrosis. *Thorax* 1999; 54: 91.
40. Grasemann H, Ratjen F. Total sputum nitrate and nitrite is raised during acute pulmonary infection in cystic fibrosis. *Am J Respir Crit Care Med* 1999; 159: 684-685.
41. Grasemann H, Ratjen F. CF-Patienten leben länger dank einer besseren Therapie. *Forschung und Praxis* 2000; 19:18-22.
42. Ratjen F, Rietschel E, Griese M, Ballmann M, Kleinau I, Döring G, Reinhardt D, Paul K for the BEAT study group. Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. *Eur Respir J* 2000; 15: 141-145.
43. Ratjen F, Kavuk I, Gärtig S, Wiesemann HG, Grasemann H. Airway nitric oxide (NO) in infants with wheezy bronchitis. *Pediatr Allerg Immunol* 2000, 11: 1-7.
44. De Blic J, Midulla F, Barbato A, Clement A, Dab I, Eber E, Green C, Grigg J, Kotecha S, Kurland J, Pohunek P, Ratjen F, Rossi C. ERS Task Force on bronchoalveolar lavage in children. *Eur Respir J* 2000, 15: 217-231.
45. Ratjen F. Reference values for bronchoalveolar lavage in children. *Monaldi Arch Chest Dis* 2000; 55: 247-250.
46. Grasemann H, Knauer N, Eijmes J, Drazen J, Ratjen F. Airway NO levels in CF patients are related to a polymorphism in the neuronal NO synthase (NOS1) gene. *Am J Respir Crit Care Med* 2000; 162: 2172-2176.
47. Ratjen F. Changes in strategies for optimal antibacterial therapy in cystic fibrosis. *Int J Antimicrob Agents* 2001; 17: 93-96.
48. Ratjen F, Comes G, Paul K, Posselt HG, Wagner TOF, Harms K for the German Board of the European Registry for Cystic Fibrosis (ERCF). Effect of continuous anti-

- staphylococcal therapy on the rate of *P. aeruginosa* acquisition in patients with cystic fibrosis. *Pediatr Pulmonol* 2001; 31: 13-16.
49. Bald M, Wingen M, Nikolaizik W, Ratjen F. Ciprofloxacin induced acute renal failure in a patient with cystic fibrosis. *Pediatr Infect Dis J* 2001; 20: 320-321.
  50. Paul K, Ratjen F, Schuster A. Pulmonale Manifestation der Mukoviszidose. *Monatsschr Kinderhkd* 2001; 149: 222-238.
  51. Ratjen F, Döring G, Nikolaizik W. Effect of inhaled tobramycin on early *Pseudomonas aeruginosa* colonisation in patients with cystic fibrosis. *Lancet* 2001; 358: 983-984.
  52. Grasemann H, Ratjen F. Different subgroups of difficult asthma in children. *Thorax*. 2001; 56: 895.
  53. Gaston B, Ratjen F, Vaughan JW, Malhotra NR, Snyder AH, Hunt JF, Gaertig S, Goldberg JB. Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. *Am J Respir Crit Care Med*. 2002; 165:387-90.
  54. Grasemann H, Storm van's Gravesande, Gaertig S, Kirsch M, Büscher R, Drazen JM, Ratjen F: Nasal nitric oxide levels in cystic fibrosis patients are associated with a neuronal synthase (NOS1) gene polymorphism. *Nitric Oxide* 2002; 6: 236-241.
  55. Nikolaizik W, Trociewicz, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. *Eur Respir J* 2002; 20: 122-126.
  56. Baraldi E., de Jongste JC, Gaston B, Alving K, Barnes PJ, Bisgaard H, Bush A, Gaultier C, Grasemann H, Hunt JF, Kisson N, Piacentini GF, Ratjen F, Silkoff P, Stick S. Measurement of nitric oxide in children, 2001. *Eur Respir J* 2002; 20: 223-237.
  57. Straub V, Ratjen F, Amthor H, Voit T, Grasemann H. Airway nitric oxide in Duchenne muscular dystrophy. *J Pediatr* 2002; 141: 132-134.
  58. Grasemann H, Ratjen F. Besonderheiten im pulmonalen NO-Stoffwechsel bei Patienten mit zystischer Fibrose. *Pneumologie* 2002 ; 56: 376-81.
  59. Neumann M, von Bredow C, Ratjen F, Griese M. Bronchoalveolar lavage protein patterns in children with malignancies, immunosuppression, fever and pulmonary infiltrates. *Proteomics* 2002, 2: 683-689.
  60. Büscher R, Eilmes KJ, Grasemann H, Knauer N, Sroka K, Insel PA, Ratjen F.  $\beta_2$ -adrenoceptor polymorphisms in cystic fibrosis lung disease. *Pharmacogenetics* 2002; 12: 347-353.
  61. Ratjen F, Hartog CM, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of cystic fibrosis patients and their modulation by treatment with dornase alfa. *Thorax* 2002; 57: 930-934.
  62. Griese M, Neumann M, von Bredow T, Schmidt R, Ratjen F. Surfactant in healthy children and in children with malignancies, immunosuppression, fever and pulmonary infiltrates. *Eur Respir J* 2002;.20: 1284-1291.
  63. Dalhoff K, Ewig S, Hoffken G, Lorenz J, Maass M, Niedermeyer J, Ratjen F, Welte T, Wilkens H; German Pathology Society. Recommendations for the diagnosis, therapy and

- prevention of pneumonia in the immunocompromised host. *Pneumologie*. 2002; 56: 807-31.
64. Grasemann H, Storm van's Gravesande K, Buscher R, Knauer N, Silverman ES, Palmer LJ, Drazen JM, Ratjen F. Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. *Am J Respir Crit Care Med* 2003; 167: 390-394.
  65. Ratjen F, Costabel U, Griese M, Paul K. Bronchoalveolar lavage findings in hypersensitivity pneumonitis. *Eur Respir J* 2003; 21: 144-148.
  66. Ratjen F, Doring G. Seminar: Cystic Fibrosis. *Lancet* 2003; 361: 681-689.
  67. Grasemann H, Storm van's Gravesande K, Böscher R, Drazen JM, Ratjen F. Effects of gender and gene variants in constitutive nitric oxide synthases on exhaled nitric oxide. *Am J Respir Crit Care Med* 2003; 167: 1113-616.
  68. Viazov S, Ratjen F, Scheidhauer R, Fiedler M, Roggendorf M. High prevalence of human metapneumovirus infection in young children and genetic heterogeneity of the viral isolates. *J Clin Microbiol* 2003; 41: 3043-5.
  69. Midulla F, de Blic J, Barbato A, Bush A, Eber E, Kotecha S, Haxby E, Moretti C, Pohunek P, Ratjen F; ERS Task Force. Flexible endoscopy of paediatric airways. *Eur Respir J* 2003; 22: 698-708.
  70. Ratjen F, Grasemann H. Cystic fibrosis and NOS3 [letter]. *Am J Respir Crit Care Med* 2004; 169:320.
  71. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Doring G, van Koningsbruggen S, Wahn U, Ratjen F; Bronchoalveolar Lavage for the Evaluation of Antiinflammatory Treatment Study Group. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. *Am J Respir Crit Care Med* 2004; 169: 719-25.
  72. Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, Ratjen F, Mullinger B, Huber RM, Maier K, Rietschel E, Scheuch G. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. *Am J Respir Crit Care Med* 2004; 169: 822-8.
  73. Borchers T, Dirsch O, Schaper J, Kreuzfelder E, Jakob H, Ratjen F. Nodular pulmonary vasculitis in a twelve-year-old boy. *Pediatr Pulmonol* 2004; 37: 181-5.
  74. Ratjen F, Konietzko N. Diabetes mellitus in cystic fibrosis. *Pneumologie* 2004; 58: 5-6.
  75. Ratjen F, Nicolai T. Paediatric bronchoscopy. *Paediatr Respir Rev* 2004;5 Suppl A:S21-2.
  76. Ratjen F. The infant with cystic fibrosis: inflammatory markers. *Paediatr Respir Rev* 2004; 5 Suppl A: S365-6.
  77. Ratjen F. Early interventions in CF. *Pediatr Pulmonol Suppl* 2004; 26: 88-90.
  78. Ratjen F, Dornase in non-CF. *Pediatr Pulmonol Suppl* 2004; 26: 154-5.

79. Grasmann H, Ratjen F. Gender-specific disease modification by NOS3. *Br J Haematol.* 2004; 126: 160
80. Griese M, Essl R, Schmidt R, Rietschel E, Ratjen F, Ballmann M, Paul K; BEAT Study Group. Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. *Am J Respir Crit Care Med* 2004; 170: 1000-5.
81. Midulla F, Guidi R, Tancredi G, Quattrucci S, Ratjen F, Bottero S, Vestiti K, Francalanci P, Cutrera R. Microaspiration in infants with laryngomalacia. *Laryngoscope* 2004; 114: 1592-6.
82. Ratjen F, Paul K, van Koningsbruggen S, Breitenstein S, Rietschel E, Nikolaizik W. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. *Pediatr Pulmonol* 2005; 39: 1-4.
83. Grasmann H, Grasmann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. *Eur Respir J* 2005 ; 25: 62-8.
84. Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Barmeier H, Ratjen F; for the Emerging Bacteria Study Group. Prospective evaluation of emerging bacteria in cystic fibrosis. *J Cyst Fibrosis* 2005; 4: 41-8.
85. Brouard J, Knauer N, Boelle PY, Corvol H, Henrion-Caude A, Flamant C, Bremont F, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, Chadelat K, Boule M, Fauroux B, Ratjen F, Grasmann H, Clement A. Influence of Interleukin-10 on airways colonization by *Aspergillus fumigatus* in cystic fibrosis patients. *J Infect Dis* 2005; 191(11):1988-91.
86. Tang GM, Hoerning A, Büscher R, O'Connor DT, Ratjen F, Grasmann H, Insel P. Human adenosine 2B receptor: SNP discovery and evaluation as a potential modifying gene in patients with cystic fibrosis. *Pharmacogenetics & Genomics*, 2005; 15(5):321-7.
87. Ratjen F, Rjabko O, Kremens B. High dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation. *Bone Marrow Transplant* 2005; 36(2):135-8.
88. Knauer N. Ratjen F. Grasmann H. Cystic fibrosis modifying genes. [German]. *Pneumologie* 2005; 59(6):395-404.
89. Hartl D. Starosta V. Maier K. Beck-Speier I. Rebhan C. Becker BF. Latzin P. Fischer R. Ratjen F. Huber RM. Rietschel E. Krauss-Etschmann S. Griese M. Inhaled glutathione decreases PGE(2) and increases lymphocytes in cystic fibrosis lungs. *Free Radical Biology & Medicine*, 2005; 39(4):463-72.
90. Ratjen F. Diagnostische Massnahmen- welche sind zur Verlaufskontrolle der Mukoviszidose sinnvoll?(Diagnostic measures – which of them are useful in the follow-up of cystic fibrosis?) *Atemw- Lungenkrkh* 2005, 31:306-310.
91. Grasmann H, Schwiertz R, Matthiesen S, Racké K, Ratjen F. Increased Arginase Activity in Cystic Fibrosis Airways. *Am J Respir Crit Care Med* 2005; 172: 1523-1528.

92. Griese M, Essl R, Schmidt R, Ballmann M, Paul K, Rietschel E, Ratjen F. Beat Study Group. Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. *Respir Res*, 2005 Nov 7;6(1):133.
93. Ratjen F. Editorial: Restoring Airway Surface Liquid in Cystic Fibrosis. *N Engl J Med*, 2006 (Jan. 19) 354(3): 291-293.
94. Ratjen F, Rietschel E; Kasel D, Schwiertz R; Starke K, Beier H, van Koningsbruggen S, Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. *J Antimicrob Chemother* 2006; 57:306-311.
95. Büscher R, Hoerning A, Patel HH, Zhang S, Grasemann H, Ratjen F, Insel PA. Frequency of P2Y<sub>2</sub> receptor Polymorphisms and haplotypes in cystic fibrosis and their impact on Ca<sup>2+</sup> influx. *Pharmacogenet Genomics* 2006; 16:199-205.
96. Stehling F, Roll C, Ratjen G, Grasemann H. Nasal nitric oxide to diagnose primary ciliary dyskinesia in newborns. *Arch Dis Child Fetal Neonatal Ed.* 2006; 91(3) F233 (May).
97. Ratjen F: What's new in CF airway inflammation: An update. *Paediatr Respir Rev* 2006, 7: Suppl 1:S70-2,
98. Ratjen F: Diagnosing and managing infection in CF. *Paediatr Respir Rev* 2006, 7: Suppl 1:S151-3.
99. Tschiedel E, Grasemann H, Ratjen F. *Mycobacterium chelonae* in a CF patient with anaplastic large cell lymphoma. *J Cyst Fibrosis*, 2006, 5(2):133-6.
100. Grasemann H. Kurtz F. Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. *Am J Respir Crit Care Med*, 2006; 174(2):208-12.
101. Ratjen F, Beier H, Grasemann H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis: authors' response. *J Antimicrob Chemother*, 2006; 58(1):223.
102. Ratjen F. Inhaled hypertonic saline produces small increases in lung function in patients with cystic fibrosis. *J. Pediatr* 2006; 149(1):142.
103. Taylor L, Corey M, Matlow A, Sweezey NB, Ratjen, F. Comparison of Throat Swabs and Nasopharyngeal Suction Specimens in Non-Sputum-Producing Patients With Cystic Fibrosis. *Pediatr Pulmonol*, 2006; 41:839-843.
104. Starosta V. Ratjen F. Rietschel E. Paul K. Griese M. Anti-inflammatory cytokines in cystic fibrosis lung disease. *Eur Resp J* 2006; 28(3):581-7.
105. Grasemann H. Schwiertz R. Grasemann C. Vester U. Racke K. Ratjen F. Decreased systemic bioavailability of L-arginine in patients with cystic fibrosis. *Resp Res* 2006; 7:87.
106. Ratjen F. Treatment of early *P.aeruginosa* infection in patients with cystic fibrosis. *Curr Opin Pulmon Med* 2006; 12:428-432
107. Subbarao P, Ratjen F. Beta2 Agonists for Asthma: The Pediatric Perspective. *Clin Rev Allergy Immunol* 2006; 31(2-3):209-18.

108. Waters V, Ratjen F. Multi-drug resistant organisms in cystic fibrosis: management and infection control issues. *Expert Rev Anti Infect Ther* 2006; 4(5):807-19.
109. Chan EY, Avcin T, Dell SD, Manson D, Cutz E, Schneider R, Ratjen F. Massive hemoptysis in an 11-year-old girl with isolated pulmonary arteries. *Pediatr Pulmonol* 2007; 42(2):177-80.
110. Henke M, Ratjen F. Mucolytics in cystic fibrosis. *Pediatr Resp Reviews*, 2007; 8:24-29.
111. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of serum antibodies in early *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *Pediatr Pulmonol* 2007; 42(3):249-55.
112. Schnabel D, Grasemann C, Staab D, Wolfmann H, Ratjen F. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Metabolic and Respiratory Effects of Growth Hormone in Children with Cystic Fibrosis. *Pediatrics* 2007; 119 (6): e1230-8.
113. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. *Pediatr Pulmonol* 2007; 42(5):471-476.
114. Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte T, Molina L, Döring G, Ratjen F. Safety and efficacy of inhaled Moli1901 in cystic fibrosis. *Chest* 2007; 131:1461-1466.
115. Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. *J Antimicrobiol Chemother*, 2007; 59(6):1135-40.
116. Grasemann H, Tschiedel E, Groch M, Klepper J, Ratjen F. Exhaled nitric oxide in children after accidental exposure to chlorine gas. *Inhal Toxicol*. 2007;19(10):895-8.
117. Ridder-Schaphorn S, Ratjen F, Hübbers A, Hüberte J, Falk S, Küster P, Schuster A, Mellies U, Löwe B, Reintjes R, Peters G, Kahl BC. Nasal Staphylococcus aureus Carriage is not a Risk Factor for Lower Airway Infection in Young Cystic Fibrosis Patients. *J Clin Microbiol*. 2007; 45(9):2979-84.
118. Ratjen F. New pulmonary therapies for cystic fibrosis. *Curr Opinion in Pulmonary Medicine*. 2007; 13(6):541-6.
119. Grasemann C, Ratjen F, Schnabel D, Reutershahn E, Vester U, Grasemann H. Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. *Eur Respir J*. 2008; 31(4):815-21.
120. Wells GD, Wilkes DL, Schneiderman-Walker J, Elmi M, Tullis E, Ratjen F, Coates AL. Reliability and Validity of the Habitual Activity Estimation Scale (HAES) In Patients with Cystic Fibrosis. *Pediatr Pulmonol* 2008; 43(4):345-53.
121. Amin R, Ratjen F. MRI: The Next Frontier for Cystic Fibrosis Clinicians? *Expert Rev Respi Med*. 2008; 2(2) 179-182.

122. Ratjen F. Recent advances in cystic fibrosis. *Paediatr Respir Rev*, 2008; 9(2):144-148.
123. Davis, SD Ratjen F. Editorial: Reduced lung function in cystic fibrosis: a primary or secondary phenotype? *Am J Respir Crit Care Med* 2008; 178(1): 2-3.
124. Coates, AL, Green M, Leung K, Chan J, Ribeiro N, Louca E, Ratjen F, Charron M, Tservistas M, Keller M. Rapid pulmonary delivery of inhaled tobramycin for *Pseudomonas* infection in cystic fibrosis: A pilot project. *Pediatr Pulmonol* 2008; 43(8): 753-759.
125. Nikolaizik WH, Vietzke D, Ratjen F. A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients. *Can Respir J*. 2008 15(5):259-62.
126. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of *Pseudomonas aeruginosa* in cystic fibrosis. *Cochrane Database Syst Rev*. 2008; 16;(3):CD006961.
127. Ratjen F. Aerosol Therapy in Cystic Fibrosis: Weighing the Evidence. *Pediatr Pulmonol* 2008; 43(S9):S3-S4
128. Wells GD, Heale L, Schneiderman JE, Wilkes DL, Atenafu E, Coates AL, Ratjen F. Assessment of body composition in pediatric patients with cystic fibrosis. *Pediatr Pulmonol*. 2008; 43(10): 1025-32.
129. Amin R, Ratjen F. Cystic Fibrosis: a review of pulmonary and nutritional therapies. *Adv Pediatr*. 2008;55:99-121
130. Corvol H, Pierre-Yves B, Brouard J, Knauer N, Chadelat K, Hennion-Caude A, Fa,amt C, Charlier C, Boule M, Faroux B, Vallet C, Feingold J, Ratjen F, Grasemann H, Clement A. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. *Pediatric Pulmonol* 2008; 43(12):1224-32.
131. Ratjen F, Bush A. Amiloride: still a viable treatment option in cystic fibrosis? *Am J Respir Crit Care Med*. 2008 ;15;178(12):1191-2.
132. Ratjen, F. Update in Cystic Fibrosis 2008. *Am J Respir Crit Care Med*. 2009 15;179(6):445-8.
133. Amin R, Noone PG, Ratjen F. Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. *Cochrane Database Syst Rev*. 2009; 15;(2):CD00748.
134. Nash EF, Stephenson A, Ratjen F, Tullis E. [Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis](#). *Cochrane Database Syst Rev*. 2009; 21; (1):CD007168. Review.
135. Al-Saleh S, Mei-Zahav M, Faughnan M, MacLusky IB, Carpenter S, Letarte M, Ratjen F. Screening for Pulmonary Arteriovenous Malformations in Children with Hereditary Hemorrhagic Telangiectasia. *Eur Respir J* 2009 Apr 22. [Epub ahead of print]

136. Ratjen F. Cystic fibrosis: Pathogenesis & future treatment strategies. *Respir Care*. 2009 54(5):595-605.
137. [Keijzer R](#), [Chiu PP](#), [Ratjen F](#), [Langer JC](#). Pulmonary function after early vs late lobectomy during childhood: a preliminary study. *J Pediatr Surg*. 2009 May;44(5):893-5.
138. Barbato A, Bertuola F, Kuehni C, Karppi M, Kotecha S, Pijnenburg MW, Ratjen F, Seddon P, Bush A. Paediatrics in Berlin. *Eur Respir J* 2009 in press
139. Bendiak G, Ratjen F. The Approach to Pseudomonas Aeruginosa in Cystic Fibrosis *Sem Respir Crit Care Med*. 2009 in press
140. Amin R, Dupuis A, Aaron SD, Ratjen F. The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Cystic Fibrosis Patients. *Chest*. 2009 June 30. [Epub ahead of print]

### Supplements and Books

1. Ratjen F, Posselt HG, Wönne R, Stöver B, Bender SW. A double blind placebo controlled trial with ambroxol and n-acetylcysteine for mucolytic treatment in cystic fibrosis. in: David Lawson (ed.): *Cystic fibrosis: Horizons*. John Wiley & Sons, New York; 1984.
2. Ratjen FA, Wiesemann HG. Variability of dynamic compliance measurements in spontaneously breathing infants, *Ped Digest* 1993; 2: 21-22.
3. Ratjen F, Schoenfeld B, Wiesemann HG. Pulmonary alveolar microlithiasis and lymphocytic interstitial pneumonitis in a ten year old girl. in: Lionel Young (ed.): *Year book of diagnostic radiology*, Mosby-Year Book Inc., Chicago; 1994.
4. Ratjen F. Mukoviszidose. In: Reinwein D, Benker G (editor) *Checkliste Endokrinologie und Stoffwechsel*. Thieme Verlag Stuttgart, New York, 436-438; 1996.
5. Ratjen F, Bredendiek M, Zheng L, Brendel M, Costabel U. Lymphocyte subsets in bronchoalveolar lavage fluid of children without bronchopulmonary disease. In: Stanley Szefer (ed.): *Year book of allergy, asthma, and clinical immunology*, Mosby-Year Book Inc., Chicago; 1996.
6. Ratjen F. Bronchoalveoläre Lavage. In: Rieger C, Wahn U, Zach M (editor): *Pädiatrische Pneumologie*. Springer Verlag Berlin, 225-230; 1999.
7. Bauernfeind A, Jungwirth R, Ratjen F. Susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients to ciprofloxacin. *Drugs* 58 (Suppl. 2): 209-210, 1999
8. Griese M, Ratjen F, Reinhardt D. Diagnose der Mukoviszidose. Klinische Symptomatik. In: Reinhardt D, Götz M, Kraemer R, Schöni MH (editor): *Mukoviszidose*. Springer Verlag Berlin, 186-191, 2001.
9. Griese M, Ratjen F, Reinhardt D. Diagnosestellung und Vorgehen bei uneindeutiger Diagnostik. In: Reinhardt D, Götz M, Kraemer R, Schöni MH (editor): *Mukoviszidose*. Springer Verlag Berlin, 221-225, 2001.

10. Ratjen F, Schuster A. Anti-inflammatorische Therapie. In: Reinhardt D, Götz M, Kraemer R, Schöni MH (editor): Mukoviszidose. Springer Verlag Berlin 288-291, 2001.
11. Ratjen F. Erkrankungen der Luftwege. In: Sitzmann (editor): Duale Reihe Pädiatrie. Thieme Verlag Stuttgart, 291-328, 2002.
12. Ratjen F. Praktische Empfehlungen zur Vermeidung mikrobieller Lungeninfektionen in der Familie.. In: Mukoviszidose e.V. (editor). Lungeninfektionen bei Mukoviszidose: Therapie und Prävention. Deutscher Ärzte-Verlag Köln, 141-148, 2002.
13. Wolstein R, Ratjen F. Inhalationshilfen. In Paul K (editor): Asthma bronchiale bei Kindern und Jugendlichen. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 162-170, 2003.
14. Ratjen F. Bronchoskopie und bronchoalveoläre Lavage. In Paul K (editor): Asthma bronchiale bei Kindern und Jugendlichen. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 91-94, 2003.
15. Ratjen F. Lungenfunktionstestung im Säuglings- und Kleinkindesalter. In Paul K (editor): Asthma bronchiale bei Kindern und Jugendlichen. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 78-83, 2003.
16. Ratjen F, Nicolai T. The infant with cystic fibrosis: inflammatory markers. Paediatr Respir Rev 2003; 83 (Suppl. 2): S27-S28.
17. Ratjen F. The infant with cystic fibrosis: inflammatory markers. Paediatr Respir Rev 2003; 83 (Suppl. 2): S373-S374.
18. Ratjen F, Grasemann H: Eosinophilic lung disorders. In: Textbook of pediatric pulmonology. N. Cobos, EG Perez-Yarza Eds., Ergon, Barcelona, Spain, 2003: pp 737-743.
19. Ratjen F, Grasemann H: Hypersensitivity pneumonitis. In: Textbook of pediatric pulmonology. N. Cobos, EG Perez-Yarza Eds., Ergon, Barcelona, Spain, 2003: pp 743-7-752.
20. Barker M, Schuster A, Dinwiddie R, Ratjen F. Sarcoidosis. In: Textbook of pediatric pulmonology. N. Cobos, EG Perez-Yarza Eds., Ergon, Barcelona, Spain 2003: pp 753-768.
21. Ratjen F (editor): Cystic fibrosis. Uni-med Verlag, Bremen, London, Boston 2004.
22. Ratjen F, Grasemann H. Cystic fibrosis. In: Paediatric pulmonary function testing. Prog Respir Res. Ed: Hammer J, Eber E. Karger AG Basel 2005, vol 33, pp 215-223.
23. Döring G, Ratjen F. Mucoviscidosis (Cystic Fibrosis). In: Encyclopedia of Molecular Cell Biology and Molecular Medicine, Vol. 8, Mass Spectrometry-based Methods of Proteome Analysis to Mucoviscidosis (Cystic Fibrosis), Molecular Cell Biology of, Ed Robert A Meyers, John Wiley & Sons, Inc., 2005
24. Webb AK, Ratjen, FA (Eds): Cystic Fibrosis. In: European Respiratory Monograph Vol. 11, Monograph 35, European Respiratory Society Journals Ltd, UK, 2006.
25. Konstant MW, Ratjen F. How do we assess The Response to Treatment. Commentaries on Chronic Airways Infection, 2007; 1(1): 7-11.

26. Ratjen F, Grasemann H. Leitsymptom Husten. In: Duale Reihe Pädiatrie. Ed: Friedrich Carol Sitzmann Thieme Verlag AG 2007, vol 3, pp 298-300.
27. Ratjen F, Grasemann H. Leitsymptom akute Atemnot. In: Duale Reihe Pädiatrie. Ed: Friedrich Carol Sitzmann, Stuttgart, Thieme 2007, vol 3, pp 300-302.
28. Ratjen F. Fehlbildungen des oberen Respirationstrakts. In: Duale Reihe Pädiatrie. Ed: Friedrich Carol Sitzmann, Stuttgart, Thieme 2007, vol 3, pp 300-302..
29. Ratjen F. Spezielle Krankheitsbilder des oberen Respirationstrakts. In: Duale Reihe Pädiatrie. Ed: Friedrich Carol Sitzmann , Stuttgart,Thieme 2007, vol 3, pp 302-312.
30. Grasemann H, Ratjen F. Fehlbildungen des unteren Respirationstrakts. In: Duale Reihe Pädiatrie. Ed: Friedrich Carol Sitzmann, Stuttgart, Thieme 2007, vol 3, pp 313-316.
31. Grasemann H, Ratjen F. Spezielle Krankheitsbilder des unteren Respirationstrakts. In: Duale Reihe Pädiatrie. Ed: Friedrich Carol Sitzmann, Stuttgart,Thieme 2007, vol 3, pp 316-336.
32. Doring G, Ratjen F. Immunology of Cystic Fibrosis. In: Cystic Fbrosis. Margaret Hodson, Duncan Geddes, Andrew Bush (Ed)., Hodder Arnold, UK 2007, 3<sup>rd</sup> Ed, pp. 69-80.
33. Ratjen F, Tullis E. Cystic Fibrosis. In: Clinical Respiratory Meidicine. Eds. Richard K. Albert, Stephen G. Spiro, James R. Jett. 3<sup>rd</sup> Ed. Mosby Elsevier 2008, pp 593-604
34. Ratjen F, Grasemann H. Neumonitis por hipersensibilidad y alteraciones pulmonares eosinófilas. In: Tratado de Neumologia Infantil. 2nd Edition. Eds: Cobos N, Pérez-Yarza EG. Ergon Madrid 2008, *in press*.
35. Lapin C, Ratjen F Airway clearance and mucolytic therapy in Rubenstein R Cystic Fibrosis

**Abstracts:**

1. Ratjen FA, Colin A, Stark AR, Mead J, Wohl MEB. Expiratory time constants as an indirect indicator of respiratory mechanics in infants and children. Am Rev Respir Dis 137: 381A; 1988.
2. Ratjen F, Zinman R, Stark AR, Wohl MEB. Volume recruitment and airflow retardation affect measurements of respiratory system compliance in the newborn. Physiologist 31: 7A; 1988.
3. Ratjen F, Zinman R, Stark AR, Wohl MEB. Der Einfluß von Veränderungen des Lungenvolumens auf die Compliance des Respirationssystems bei unsedierten Neugeborenen. Monatsschr Kinderheilkd 137: 19A; 1989.
4. Zinman R, Ratjen F, Wohl MEB. A new technique to detect flow limitation in partial expiratory flow-volume curves. Am Rev Respir Dis 139: 339A; 1989.
5. Ratjen FA, Wiesemann HG. Reproduzierbarkeit und Variabilität der dynamischen Compliance im Neugeborenenalter. Monatsschr Kinderheilkd 139: 57A; 1991.
6. Ratjen F, Grasemann H, Wiesemann HG, Stephan U. 2 year mortality in cystic fibrosis according to pulmonary function. Pediatr Pulmonol Suppl 9: 261A; 1993.

7. Ratjen F, Bredendiek M, Brendel M, Wachtmeister A, Costabel U. Bronchoalveolar lavage in normal children - differential cell counts and recovery. *Eur Respir J* 6: 617s; 1993.
8. Ratjen F, Bredendiek M, Brendel M, Costabel U. Differentialzytologie und Immunophänotypisierung der bronchoalveolären Lavage bei lungengesunden Kindern. *Monatsschr Kinderheilkd* 142: 244A; 1994.
9. Ratjen F, Welker J, Trost A, Spangenberg P, Wiesemann HG. The effect of rapid thoracoabdominal compressions on intracerebral pressure in newborn lambs. *Eur Respir J* 7: 992A; 1994.
10. Braun J, Dalhoff K, Ratjen F. Different protein-composition of BALF in healthy children and adults: Technical and clinical implications. *Eur Respir J* 7: 228A ; 1994.
11. Ratjen F, Steinkamp G, Wiesemann HG, Bauernfeind A, Döring G, v d Hardt H. for the German Multicenter Study Group. Prevention of chronic pseudomonas aeruginosa infection by early inhalation therapy with tobramycin. *Pediatr Pulmonol Suppl*10: 255A; 1994.
12. Ratjen F, Costabel U, Havers W. Diagnostische Wertigkeit der bronchoalveolären Lavage bei immunsupprimierten Kindern. *Monatsschr Kinderheilkd* 143: 185A; 1995.
13. Grasemann H, Ioannidis I, Ratjen F. Stickoxid in Serum und bronchoalveolärer Lavage von Kindern mit entzündlichen Lungenerkrankungen. *Monatsschr Kinderheilkd* 143: 172A; 1995.
14. Büscher F, Reidemeister C, Ratjen F. Einseitige Lungentransplantation bei einem 11 jährigen Jungen mit cystischer Fibrose. *Monatsschr Kinderheilkd* 143: 271A; 1995.
15. Ratjen F, Bruch J. Size correction of bronchoalveolar lavage volume in children. *Eur Respir J* 8: 118A; 1995.
16. Ratjen F, Costabel U, Havers W. Differential cytology of bronchoalveolar lavage in immunosuppressed children with pulmonary infiltrates. *Eur Respir J* 8: 521A; 1995.
17. Braun J, Ratjen F, Dalhoff, Wießmann KJ. Technische Aspekte der Proteinbestimmung in bronchoalveolärer Lavage (BAL) - Einfluß von Alter und Lavagevolumen. *Med Klin* 90: 283A; 1995.
18. Rath P, Ratjen F, Ansorg R. Diversity of Aspergillus species in cystic fibrosis. *Pediatr Pulmonol Suppl* 12: 246A; 1995.
19. Ratjen F, Bruch J, Costabel U. Altersabhängigkeit von Surfactantphospholipiden in der bronchoalveolären Lavage von lungengesunden Kindern. *Pneumologie* 50 S1: 75A; 1996.
20. Ratjen F, Dalhoff K, Havers W, Braun J. Erhöhte Neutrophilenprodukte und gestörte Kapillarpermeabilität bei Pneumonien immunsupprimierter Kinder. *Pneumologie* 50 S1: 145A; 1996.
21. Grasemann H, Ioannides, De Groot H, Ratjen F. Nitric oxide in the airways in cystic fibrosis. *Am J Respir Crit Care Med* 153: 70A; 1996.
22. Ratjen F, Costabel U, Havers W. Differentialzytologie der bronchoalveolären Lavage in der Diagnostik von Pneumonien bei immunsupprimierten Kindern. *Monatsschr Kinderheilkd* 144: 584-585A; 1996.

23. Ratjen F, Grasemann H, Wolstein R, Wiesemann HG. Pressure transmission at higher jacket pressures during rapid thoracoabdominal compressions in young infants. *Eur Respir J* 9: 225A; 1996.
24. Ratjen F, Wolstein R, Grasemann H, Wiesemann HG. Flow limitation assessed by isovolume pressure flow curves during rapid thoracoabdominal compressions in infants. *Eur Respir J* 9: 26A; 1996.
25. Grasemann H, Ioannidis I, de Groot H, Ratjen F. Soluble metabolites of nitric oxide in airway secretions of patients with cystic fibrosis. *Eur Respir J* 9: 357A; 1996
26. Grasemann H, Michler E, Ioannidis I, de Groot H, Ratjen F. Airway nitric oxide in CF lung disease. *Pediatr Pulmonol Suppl* 13: 331A; 1996.
27. Grasemann H, Wiesemann HG, Ratjen F. Exhaled nitric oxide concentrations in patients with cystic fibrosis. *Monatsschr Kinderhkd* 144: 1040A; 1996.
28. Knauer S, Ratjen F. Fettbeladene Makrophagen in der BAL bei lungenkranken und gesunden Kindern. *Monatsschr Kinderhkd* 1997; 145: 315A; 1997.
29. Grasemann H, Ioannidis I, Ratjen F. Niedrige NO Metabolit Konzentrationen im Sputum von CF Patienten mit fortgeschrittener Lungenerkrankung. *Monatsschr Kinderhkd* 144: 314A; 1997.
30. Grasemann H, Tomkiewicz RP, Ioannidis I, Ramirez OE, Rubin BK, Ratjen F. Metabolites of nitric oxide and viscoelastic properties of airway secretions in cystic fibrosis. *Am J Respir Crit Care Med* 155:A46; 1997.
31. Grasemann H, Gaertig S, Wiesemann HG, Ratjen F. Airway nitric oxide in patients with cystic fibrosis after infusion of L-arginine. *Eur Respir J* 1997 ; 10: 269-270A.
32. Ratjen F, Rietschel E, Ballmann M, Griese M, Döring G, Kleinau I, Wahn U, Paul K. Airway inflammation in CF patients with normal lung function. *Eur Respir J* 1997 ; 10: 302A.
33. Kleinau I, Ratjen F, Rietschel E, Ballmann M, Griese M, Döring G, Wahn U, Paul K. Lymphocyte subsets in BAL fluid of CF patients. *Eur Respir J* 1997; 10: 303A.
34. Gärtig SS, Grasemann H, Wiesemann HG, Ratjen F. Die Wirkung von L-Arginin auf die NO Konzentration in den unteren und oberen Luftwegen bei Patienten mit primärer Ziliendyskinesie. *Monatsschr Kinderhkd* 1998,146: 291-292A.
35. Grasemann H, Gaertig S, Wiesemann HG, Konietzko N, Ratjen F. Effect of L-arginine infusion on airway nitric oxide and pulmonary function in ciliary dyskinesia patients. *Am J Respir Crit Care Med* 1998,157: 795A.
36. Liu Y, Gaertig S, Dai H, Ratjen F, Costabel U. Nitrate levels in BAL fluid from patients with extrinsic allergic alveolitis, idiopathic pulmonary fibrosis and sarcoidosis. *Am J Respir Crit Care Med* 1998,157: 70A.
37. Grasemann H, Gaston B, Ratjen F. Decreased nitrosothiol (RSNO) concentration in BAL fluid of CF patients with normal lung function. *Eur Respir J* 1998,12: 235A.
38. Rietschel E, Ballmann M, Griese M, Ratjen F, Döring G, Kleinau I, Tinschmann P, Wahn U,

- Paul K. Can normal neutrophil count in BAL predict a benign pulmonary course in stable CF patients? *Eur Respir J* 1998,12: 235A.
39. Liu Y, Gärtig S, Dai H, Ratjen F, Costabel U. BAL nitrate levels in patients with lung disease. *Eur Respir J* 1998,12: 254A.
  40. Ratjen F, Gaertig S, Grasemann H. Effect of inhaled nitric oxide (NO) on lung function in cystic fibrosis. *Eur Respir J* 1998,12: 446A.
  41. Ratjen F, Braun J. Erhöhte Kapillarpermeabilität bei immunsupprimierten Kindern mit Pneumonie. *Monatschr Kinderhkd* 1998,146: 227A
  42. Ratjen F, Hombach S, von der Hardt H, Ballmann M. The effect of inhaled tobramycin on *Pseudomonas aeruginosa* colonisation in patients with cystic fibrosis. *Pediatr Pulmonol* 1998,Suppl 17: 321A.
  43. Ratjen F, Hübner K, Bauernfeind A. *Alcaligenes xylosoxidans* subsp.*xylosoxidans*: prevalence and spread in CF patients. *Pediatr Pulmonol* 1998; Suppl 17: 321A.
  44. Bauernfeind A, Roller C, Schneider I, Ratjen F. Prevalence of *Burkholderia gladioli* and *Burkholderia vietnamiensis* in cystic fibrosis. *Pediatr Pulmonol* 1998,Suppl 17: 322A;.
  45. Bauernfeind A, Schneider I, Palm A, Ratjen F. Prevalence and transmission of *Burkholderia multivorans* among CF patients. *Pediatr Pulmonol* 1998,Suppl 17: 322A.
  46. Grasemann H, Gaston B, Ratjen F. Deficiency of bronchodilator S-nitrosothiol in CF patients with mild lung disease. *Pediatr Pulmonol* 1998; Suppl 17: 349A.
  47. Paul K, Ballmann M, Döring G, Griese M, Kleinau I, Ratjen F, Reinhardt D, Rietschel E, von der Hardt H, Wahn U. Airway inflammation in CF patients with good pulmonary function-baseline data from the multicenter BEAT study. *Pediatr Pulmonol* 1998; Suppl 17: 383A.
  48. Bauernfeind A, Jungwirth R, Ratjen F. Antibiotic resistance of *Pseudomonas aeruginosa* strains isolated from cystic fibrosis patients. *J Infect Dis* 1998,Suppl 35: 209A.
  49. Ratjen F, Kavuk I, Gaertig S, Grasemann H. Stickoxid (NO) Konzentrationen bei Säuglingen mit obstruktiver Bronchitis. *Monatschr Kinderhkd* 1999,147: 60A.
  50. Ratjen F, Paul K. BAL Differentialzytologie bei Kindern mit exogen allergischer Alveolitis. *Monatschr Kinderhkd* 1999,147: 79A.
  51. Ratjen F, Rietschel E, Ballmann M, Griese M, Kleinau I, Paul K. Sequential analysis of BAL fluid cytology in CF patients with normal lung function. *Eur Respir J* 1999 ; Suppl 30: 284A.
  52. Ratjen F, Kavuk I, Wiesemann HG, Grasemann H. Airway nitric oxide (NO) in wheezy infants with acute upper airway infection. *Eur Respir J* 1999,Suppl 30: 37A.
  53. Satake N, Lange Ch, Ratjen F, Guzman J, Costabel U. Role of exhaled nitric oxide (NO) in exhaled air as an index of inflammation in interstitial lung disease. *Eur Respir J* 1999,Suppl 30: 101A..
  54. Ratjen F, Ballmann M, Griese M, Rietschel E, Kleinau I, Paul K. Differences in BAL neutrophils between CF patients homozygous and compound heterozygous for DF 508. *Pediatr Pulmonol* 1999,Suppl 19: 415A.

55. Bauernfeind A, Eberlein E, Ratjen F. Susceptibility of *Stenotrophomonas* to moxifloxacin and ciprofloxacin alone and in combination with colistin. *Pediatr Pulmonol Suppl* 1999,19: 391A.
56. Ratjen F. Changes in strategies for optimal antibacterial therapy. *Anti Infect Drugs Chemother* 2000,17: 126A.
57. Ratjen F, Costabel U, Paul K. Differential cytology of BAL fluid in children with hypersensitivity pneumonitis. *Curr Pneumonol* 2000,4: 16A.
58. Büscher R, Grasemann H, Eilmes KJ, Knauer N, Hübner K, Insel PA, Ratjen F. Polymorphisms of the  $\beta$ -2 adrenergic receptor in patients with cystic fibrosis. *Eur Respir J* 2000,Suppl 31: 153s.
59. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high dose tobramycin preparations in patients with cystic fibrosis. *Eur Respir J Suppl* 2000,31:154s.
60. Griese M, Neumann M, Schmidt R, Ratjen F. Surfactant status in immunosuppressed children with hemalologic malignancies and pulmonary infections. *Eur Respir J* 2000,Suppl 31: 196s.
61. Lange C, Satake N, Liu Y, Ratjen F, Guzman J, Costabel U. Exhaled nitric oxide and nitrate levels in BAL and induced sputum in interstitial lung disease. *Eur Respir J* 2000 Suppl 31: 214s.
62. Ratjen F, Paul K. BAL differential cytology in children with hypersensitivity pneumonitis. *Eur Respir J* 2000,Suppl 31: 482s.
63. Grasemann H, Knauer N, Büscher R, Ratjen F. Variability of exhaled nitric oxide (NO) in cystic fibrosis is associated with a polymorphism in the neuronal NO synthase (NOS1) gene. *Eur Respir J* 2000,Suppl 31: 512s.
64. Ratjen F. Aktuelle Aspekte der Mikrobiologie bei Mukoviszidose. *Kinderärztl Praxis* 2000,71: V12.
65. Buescher R, Insel PA, Knauer N, Eilmes KJ, Grasemann H, Ratjen F. Disease modifying genes in CF:  $\beta$ -2 adrenergic receptor. *Pediatr Pulmonol Suppl* 2000, 20: 211A.
66. Grasemann H, Büscher R, Knauer N, Gärtig S, Hübner K, Ratjen F. Disease modifying genes in CF: neuronal NO synthase (NOS1). *Pediatr Pulmonol* 2000, Suppl 20: 212A.
67. Griese M, Koch N, Paul K, Rietschel E, Ballmann M, Ratjen F, Schams A, Beck J. Biophysical properties of pulmonary surfactant in cystic fibrosis. *Pediatr Pulmonol Suppl* 2000; 20: 297A.
68. Nikolaizik W, Ratjen F. Therapie der *Burkholderia cepacia* Infektionen bei Patienten mit cystischer Fibrose. *Monatschr Kinderhkd* 2001,149: 194A
69. Nikolaizik W, Trociewicz K, Ratjen F. Bronchiale Reaktionen auf die Inhalation hochdosierter Tobramycin-Lösungen bei Patienten mit cystischer Fibrose. *Monatschr Kinderhkd* 2001; 149: 134-135A.
70. Grasemann H, Storm van's Grasesande K, Gärtig S, Knauer N, Büscher R, Drazen JM, Ratjen F. Die Variabilität von FeNO korreliert bei Patienten mit CF nicht mit Mutation in der

- endothelialen NO-Synthase (NOS3). *Monatschr Kinderhlkd* 2001; 149: 204A.
71. Gärtig S, Knauer N, Büscher R, Ratjen F, Grasemann H. Die nasale NO-Konzentration korreliert bei CF Patienten mit einem Polymorphismus im Gen der neuronalen NO-Synthase (NOS1). *Monatschr Kinderhlkd* 2001; 149: 204-205A.
  72. Ratjen F. Inflammatorische Prozesse bei CF. *Monatschr Kinderhlkd* 2001; 149: 204A.
  73. Braun J, Hartog M, Wermelt J, Paul K, Dalhoff K, Ratjen F. Early signs of MMP/TIMP imbalance in cystic fibrosis. *Eur Respir J* 2001; Suppl. 33: 8s.
  74. Gärtig S, Ratjen F, Nikolaizik WH, Büscher R, Grasemann H. Nasal NO concentrations and colonisation of lower airways with *P. aeruginosa* are associated with variants in the neuronal NO synthase (NOS1) gene in CF patients. *Eur Respir J* 2001; Suppl. 33: 8s.
  75. Grasemann H, Ratjen F. Gender differences in exhaled nitric oxide concentrations (FeNO) in healthy individuals. *Eur Respir J* 2001; Suppl. 33: 258s.
  76. Nikolaizik WH, Ratjen F. Treatment of *Burkholderia cepacia* infection in patients with cystic fibrosis. *Eur Respir J* 2001; Suppl. 33: 538s.
  77. Worlitzsch D, Ratjen F, Rietschel E, Botzenhart K, Döring G. Inflammatory markers in exhaled breath condensate and bronchoalveolar lavage of patients with cystic fibrosis. *Pediatr Pulmonol Suppl* 2001; Suppl. 22: 277A.
  78. Worlitzsch D, Viglio S, Ulrich M, Schuster A, Meyer KC, Iadarola P, Luisetti M, Ratjen F, Botzenhart K, Döring G. Elastin degradation in the airways of patients with cystic fibrosis decreases with age. *Pediatr Pulmonol Suppl* 2001; Suppl. 22: 278A.
  79. Ratjen F, Hartog M, Wermelt J, Paul K, Braun J. Matrix metalloproteinases in BAL fluid of CF patients with mild lung disease. *Pediatr Pulmonol Suppl* 2001; Suppl. 22: 386A.
  80. Büscher R, Grasemann H, Eilmes KJ, Knauer N, Insel PA, Ratjen F.  $\beta_2$ -Adrenergic receptor polymorphisms and altered lung function in cystic fibrosis. *FASEB J* 2001; 15: 220A.
  81. Grasemann H, Storm van's Gravesande K, Büscher R, Knauer N, Silverman ES, Drazen JM, Ratjen F. Variants in the endothelial NO synthase (NOS3) genes and airway NO in cystic fibrosis. *Am J Respir Crit Care Med* 2001; 163:658A.
  82. Straub V, Ratjen F, Amthor H, Voit T, Grasemann H. Exhaled nitric oxide concentrations are reduced in patients with Duchenne muscular dystrophy. *Neuromuscular Disorders* 2001; 11:631.
  83. Grasemann H, Sroka K, Nikolaizik WH, Ratjen F. Oral L-arginine therapy in patients with cystic fibrosis: a pilot study. *Eur Respir J* 2002; 20 Suppl 38:340s.
  84. Jung A, Ratjen F, Griese M, Rietschel E, Ballmann M, Döring G, Paul KP. Diagnostic values of airway samples and serum antibodies for *P. aeruginosa* in cystic fibrosis. *Eur Respir J* 2002; 20 Suppl 38:1367s.
  85. Paul KP, Chen C, Schink T, Ballmann M, Döring G, Griese G, Ratjen F. Longitudinal evaluation of airway inflammation in stable CF patients by bronchoalveolar lavage (BAL) and influence of rhDNAse. *Eur Respir J* 2002; 20 Suppl 38:3274s

86. Jung A, Shute JK, Chen CIU, Ballman M, Griese M, Ratjen F, Rietschel E, Paul KP. Influence of long-term inhaled rhDNase on free and total IL-8 concentration in BAL fluid in cystic fibrosis. *Eur Respir J* 2002; 20 Suppl 38:3285s.
87. Büscher R, Eilmes KJ, Grasemann H, Torres BH, Knauer N, Insel PA, Ratjen F. Polymorphisms of the  $\beta_2$ -adrenergic receptor gene: modifiers of lung disease in cystic fibrosis? *Pharmacologist* 2002; 44 Suppl 2:A167-A168
88. Grasemann H, Ratjen F, Amthor H, Voit T, Straub V. Die neuronale NO Synthase (NOS1) und NO in der Ausatemluft - Untersuchungen an Patienten mit Muskeldystrophie vom Typ Duchenne. *Monatsschr Kinderheilkd* 2002; 150:419-420.
89. Ratjen F. Diagnosis of infection in infants. *J Cystic Fibrosis* 2002; 1:Suppl 1: S1,
90. Worlitzsch D, Ulrich M, Rietschel E, Ratjen F, Botzenhart K, Döring G. Exhaled breath condensate: how valuable to monitor lung inflammation? *J Cystic Fibrosis* 2002; 1:Suppl 1:S9.
91. Ratjen F, Paul K, Rietschel E, Nikolaizik W. Treatment with rhDNase reduces DNA levels in BAL Fluid of CF Patients with Mild Lung Disease. *Pediatric Pulmonol* 2002; Suppl 24:385A
92. Paul K, Ballmann M, Griese M, Rietschel E, Chen C, Schink T, Shute JK, Doring G, Ratjen F. Effect of rhDNase of Endobronchial Inflammation in CF Patients with Mild Lung Disease: Results of the Multi-Center BEAT Study. *Pediatric Pulmonol* 2002; Suppl 24:386A.
93. Grasemann H, Ratjen F, Amthor H, Voit R, Straub V. Contribution of neuronal NO synthase (NOS1) to FENO – evidence from Duchenne muscular dystrophy. *Am J Respir Crit Care Med* 2002; 165:340A,
94. Ratjen F, Nikolaizik WH, Büscher R, Grasemann H. Effect of an angiotensin I-converting enzyme gene polymorphism on the clinical course of patients with cystic fibrosis. *Pediatric Pulmonol* 2003; Suppl 25:106A.
95. Griese M, Hart D, Starostov V, Rebhan C, Ramakers J, Latzin P, van Koenigsbruggen S, Hubner R, Ratjen F, Nicolai T, Rietschel E, Krauss-Etschmann S. Soluble and Cellular Constituents of Bronchoalveolar Lavage (BAL) Before and After the Inhalation of Gluthathion (GSH) in Cystic Fibrosis. *Pediatric Pulmonol* 2003; Suppl 25:243A.
96. Grasemann H, Hafften A, Kirsch M, Ratjen F. NO metabolite and interleukin-6 production by human airway epithelial cells. *Eur Respir J* 2003; 22 Suppl 45:456s.
97. Grasemann H, Nikolaizik WH, Büscher R, Ratjen F. No association of angiotensin I-converting enzyme gene polymorphism and pulmonary function in cystic fibrosis. *Eur Respir J* 2003; 22 Suppl 45:173s.
98. Grasemann H, Kirsch M, Hafften A, de Groot H, Ratjen F. Profile of nitric oxide metabolites differs between stimulated airway epithelial cells and alveolar macrophages. *Am J Respir Crit Care Med* 2003; 167:A205.
99. Griese M, Ramakers J, Krasselt A, Meyer T, Rietschel E, van Koenigsbruggen S, Fischer R, Huber R, Ratjen F, Meier K, Fuerst P, Scheuch G. Optimized Aerosol Delivery of Gluthathion (GSH) to Patients with Cystic Fibrosis (CF) Increases Alveolar GSH Concentration. *Am J Respir Crit Care Med* 2003; 167:A919.

100. Paul KP, Rietschel E, Ballmann M, Griese M, Chen CI, Schink T, Shute JK, Doering G, Ratjen F. Longitudinal Evaluation of Airway Inflammation in Stable Cystic Fibrosis (CF) Patients by Bronchoalveolar Lavage (BAL) and Influence of rhDNase. *Am J Respir Crit Care Med* 2003; 167:A920.
101. Ulrich M, Prömm F, Schmid P, Schirle M, Priemer M, Ratjen F, Worlitzsch D, Lee JJ, Checkel J, Döring G. Nitration of tyrosine residues in inflamed lungs of CF patients is restricted to eosinophil granule proteins. *J Cystic Fibrosis* 2003; 2:Suppl 1:S28..
102. Knauer N, Brouard J, Corvol H, Henrion-Caude A, Boelle PY, Flamant C, Chadelat K, Miesch MC, Bremont F, Delaisi B, Duhamel J, Marguet C, Roussey M, Boulé M, Fauroux B, Ratjen F, Grasemann H, Clément A. Potential role of Interleukin-6 gene variants in the defence against airway *Pseudomonas aeruginosa* infection in cystic fibrosis patients. *Pediatric Pulmonol* 2004; Suppl 27:104A.
103. Grasemann H, Schwirtz R, Racké K, Ratjen F. Arginase activity in sputum of patients with cystic fibrosis. *Pediatric Pulmonol* 2004; Suppl 27:241A.
104. Ratjen F, Grasemann H, Döring G. The role of *P. aeruginosa* antibodies for defining airway infection with *P. aeruginosa* in CF patients. *Pediatric Pulmonol* 2004; Suppl 27:263A.
105. Grasemann H, Schwirtz R, Racké K, Ratjen F. Arginase in patients with cystic fibrosis airway disease. *Eur Respir J* 2004; 24 Suppl 48:213s.
106. Griese M, Hart D, Starostov V, Rebhan C, Maier K, Beck-Speier I, Becker B, Ramakers J, Latzin P, van Koenigsbruggen S, Huber R, Ratjen F, Kraus-Etschmann S, Rietschel E. Exploration of bronchoalveolar lavage (BAL) constituents before and after the inhalation of glutathione (GSH) in cystic fibrosis. *J Cystic Fibrosis* 2004; 1:Suppl 1: S28.
107. Brouard J, Knauer N, Boelle PY, Corvol H, Henrion-Caude A, Flamant C, Bremont F, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, Chadelat K, Boule M, Fauroux B, Rajen F, Grasemann H, Clement A. Influence of Interleukin-10 on airways colonization by *Aspergillus fumigatus* in cystic fibrosis patients. *J Cystic Fibrosis* 2005; 4: Suppl 1:S7.
108. Ridder-Schaphorn S, Breitkopf C, Ritzerfeld B, Dübbers A, Häberle J, Falk S, Küster, Schuster A, Ratjen F, Sinha B, Peters G, Kahl BC. Preliminary results of a longitudinal study observing the impact of *Staphylococcus aureus* nasal carriage on colonization of the airways in young CF patients. *J Cystic Fibrosis* 2005; 4: Suppl 1:S38.
109. Nikolaizik WH, Vietzke D, Ratjen F. Comparison of tobramycin 80 mg (IV-preparation) and 300 mg solution inhaled twice daily for chronic *P. Aeruginosa* infection. *J Cystic Fibrosis* 2005; 4: Suppl 1:S53.
110. Ratjen F, Griese M, Ballmann M, Rietschel E, Paul K for the BEAT study group. Dornase alpha in pediatric CF patients with normal lung function – Effects on airway inflammation. *Pediatric Pulmonol* 2005; Suppl 28: S12.2.
111. Buescher R, Hoerning A, Patel HH, Zhang S, Ratjen F, Grasemann H, Insel PA. The P2Y<sub>2</sub>-receptor polymorphisms ARG321SER and ARG334CYS: Expression in cystic fibrosis and impact on CA<sup>3+</sup>Influx. *Pediatric Pulmonol* 2005; Suppl 28: 25A.
112. Grasemann H, Schwirtz R, Ratjen F. Increased systemic arginase activity and L-arginine deficiency in CF patients with pulmonary exacerbation. *Pediatric Pulmonol* 2005; Suppl 28: 144A.

113. Corvol H, Vallet C, Brouard J, Knauer N, Boelle P, Henrion-Caude A, Miesch M, Chadelat K, Boule M, Fauroux B, Ratjen F, Grasemann H, Clement A. Influence of TGF- $\beta$ 1 genotype on lung function in cystic fibrosis patients. *Pediatric Pulmonol* 2005; Suppl 28: 172A.
114. Brouard J, Corvol H, Vallet C, Boelle P, Knauer N, Henrion-Caude A, Miesch M, Chadelat K, Boule M, Fauroux B, Ratjen F, Grasemann H, Clement A. Association of TNF polymorphisms with decline in lung function in cystic fibrosis. *Pediatric Pulmonol* 2005; Suppl 28: 175A.
115. Ratjen F, Mellies U, Starke K, Brunar H, Laliberte TW, Widmann R, Molina L, Grasemann H. An evaluation of the safety and tolerability of multiple rising dose regimens of aerolized MOL1901 in patients with cystic fibrosis. *Pediatric Pulmonol* 2005; Suppl 28: 219A.
116. Grasemann H, Kurtz F, Ratjen F. Inhalation of nebulized L-arginine increases exhaled nitric oxide and improves pulmonary function in patients with cystic fibrosis. *Pediatric Pulmonol* 2005; Suppl 28: 339A.
117. Worlitzsch D, Ulrich M, Ratjen F, Rietschel E, Schuster A, Doering G. Comparison of bronchoalveolar lavage and exhaled breath condensate techniques for the measurement of inflammatory markers in cystic fibrosis. *Pediatric Pulmonol* 2005; Suppl 28: 362A.
118. Buscher R, Hoering A, Grasemann H, Ratjen F, Instel PA. Analysis of three frequent polymorphisms of the P2Y(2) receptor gene, a potential modifier of lung disease in cystic fibrosis (CF). *FASEB Journal* 2005: 19:1096A.
119. Knauer N, Brouard J, Henrion-Caude A, Corvol H, Boelle PY, Flamant C, Boulé M, Fauroux B, Ratjen F, Grasemann H, Clément A. Interleukin-6 gene variants are associated with early Pseudomonas infection in cystic fibrosis. *Eur Respir J* 2005; 26:Suppl 49727s.
120. Brouard J, Knauer N, Henrion-Caude A, Corvol H, Boelle PY, Flamant C, Boulé M, Fauroux B, Ratjen F, Grasemann H, Clément A. Interleukin-10 genotypes and airways colonization by *Aspergillus fumigatus* in cystic fibrosis patients. *Eur Respir J* 2005; 26 Suppl 49:403s.
121. Grasemann H, Kurtz F, Ratjen F. Effect of inhaled L-arginine on airway nitric oxide in cystic fibrosis patients. *Eur Respir J* 2005; 26 Suppl 49:240s.
122. Grasemann H, Ratjen F: Methodological aspects of airway nitric oxide measurements in young infants. *Proceedings of the American Thoracic Society*, 2006; 3: A276.
123. Grasemann H, Grasemann C, Schnabel D, Ratjen F: Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO formation but decreased exhaled NO in patients with cystic fibrosis. *Proceedings of the American Thoracic Society*, 2006; 3: A408.
124. Amin R, Balkovec S, Ratjen F, Subbarao P: The effect of respiratory rate, tidal volume and temperature on exhaled breadth condensate volume. *Proceedings of the American Thoracic Society*, 2006; 3: A482.
125. Ratjen F: Place of inhaled antibiotics in cystic fibrosis care. *European Cystic Fibrosis Conference*, Copenhagen, 2006, June 14-17.
126. Brouard J, Corvol H, Boelle PY, Knauer N, Valler C, Henrion-Caude A, Boule M, Fauroux B, Ratjen F, Grasemann H, Clément A: Influence of tumor necrosis factor gene polymorphisms on lung disease progression in children with Cystic Fibrosis. *J Cystic Fibrosis* 2006: 5: Suppl

1S5(19).

127. Ratjen F, Stehling F, Starke K, Brunar H, Laliberte T, Widmann R, Molina L, Grasemann H. Safety, tolerability and efficacy of multiple, rising doses of aerolized Moli1901 in CF patients. *J Cystic Fibrosis* 2006; 5: Suppl 1 S11(45).
128. Ridder-Schaphorn S, Breitkopf C, Ritzerfeld B, Dübbbers, Häberle J, Falk S, Küster P, Schuster A, Ratjen, F, Mellies U, Löwe B, Reintjes R, Peters G, Kahl BC. Dynamics of the *Staphylococcus aureus* nasal carriage and upper airway colonization/infection in young cystic fibrosis patients. *J Cystic Fibrosis* 2006; 5: Suppl 1S19(84).
129. Ratjen F, Munck A, Campello V. Safety of inhaled tobramycin neuliser solution for treatment of early *Pseudomonas aeruginosa* infection: First results from the ELITE study. *J Cystic Fibrosis* 2006; 5: Suppl 1 S43(187).
130. Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Döring G. Diagnostic value of *Pseudomonas aeruginosa* antibodies in Cystic Fibrosis. *J Cystic Fibrosis* 2006; 5(1): S19(84).
131. Grasemann H, Faerber N, Buecher R, Lax H, Ratjen F: The angiotensin 1 converting enzyme (ACE) gene modifies lung disease in children with cystic fibrosis. *Pediatric Pulmonol* 2006; Suppl 29:182A.
132. Ratjen F, Strehling F, Starke K, Brunar H, Williams T, Widmann R, Molina L, Grasemann H. Safety and efficacy of aerosolized Moli1901 in patients with cystic fibrosis. *Pediatric Pulmonol* 2006; Suppl 29:241A.
133. Subbarao P, Balkovec S, Solomon M, Ratjen F: A Pilot Study of Safety and Tolerability of Inhaled Hypertonic Saline in Infants with Cystic Fibrosis. *Pediatric Pulmonol* 2006; Suppl 29:244A.
134. Ratjen F, Munck A, Campello V. Inhaled tobramycin neuliser solution for treatment of early *Pseudomonas aeruginosa* infection: First results from the ELITE study. *Pediatric Pulmonol* 2006; Suppl 29:314A.
135. Lam W, Tjon J, Seto W, Dekker A, Wong C, Atenafu E, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F: Determination of a once-daily dosing regimen for tobramycin in paediatric cystic fibrosis patients. *Pediatric Pulmonol* 2006; Suppl 29:341A.
136. Grasemann H, Grasemann C, Schnabel D, Ratjen F: Growth hormone therapy results in increased L-arginine and nitrate concentrations in serum but decreased exhaled nitric oxide in patients with cystic fibrosis. *Pediatric Pulmonol* 2006; Suppl 29:365A.
137. Wilkes DL, Schneiderman-Walker J, Wells GD, Lands LC, Selvadurai HC, Corey M, Ratjen F, Coates AL: Bone mineral density, lung health and habitual physician activity in children with cystic fibrosis. *Pediatric Pulmonol* 2006; Suppl 29:396A.
138. Wells GD, Wilkes DL, Noseworthy MD, Rayner T, Schneiderman-Walker J, Elmi M, Selvadurai H, Ratjen F, Tein I, Coates AL: Abnormalities in muscle metabolism in CF patients. *Pulmonol* 2006; Suppl 29:409A.
139. Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F. A multicenter, randomized double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. *Pediatric Pulmonol* 2006; Suppl 29:516A.

140. Bhattacharjee R, Al-Saleh S, MacLusky I, Ratjen F, Dell SD. The Role of Bilateral Lavage in Bronchoscopy in the Diagnosis of Lung Infection. *Am J Resp Crit Care Med* 2007; 175: A422.
141. Grasemann H, Tschiedel E, Ratjen F. Exhaled Nitric Oxide in Children after Accidental Exposure to Chlorine Gas. *Am J Resp Crit Care Med* 2007; 175: A723.
142. Ratjen F, Wolf B, Lax H, Grasemann H. Allergic sensitization in patients with cystic fibrosis: Longitudinal assessment and relation to exhaled nitric oxide. *Am J Resp Crit Care Med* 2007; 175: A934.
143. Taylor L, Ratjen F. The CF family teen teaching day – do the benefits outweigh the risks? *J Cystic Fibrosis* 2007; 6: Suppl 1 S72 (293).
144. Corvol H, Boelle P, Brouard J, Knauer N, Henrion-Caude A, Cadelat K, Flamant C, Charlier C, Boule M, Farroux B, Vallet C, Feingold J, Ratjen F, Grasemann H, Clement A. Genetic Variations in Inflammatory Mediators Influence Lung Disease Progression in Cystic Fibrosis. *Pediatr Pulmonol* 2007; Suppl 30: 214A.
145. Al-Saleh S, Grasemann H, Dell S, Waters V, Yau Y, Martin S, Ratjen F. Induced Sputum Compared with Expecterated Sputum to Identify Respiratory Pathogens in Children with Cystic Fibrosis. *Pediatric Pulmonol* 2007; Suppl 30:330A
146. Coates AL, Leung K, Green M, Chan J, Ribeiro N, Martin S, Menges G, Keller M, Charron M, Ratjen F. A Rapid Way To Deliver High Doses of Tobramycin To The Airways of Adult and Pediatric Patients with Cystic Fibrosis (CF). *Pediatric Pulmonol* 2007; Suppl 30:343A
147. Tjon JA, Murphy L, Seto W, Atenafu E, Wong C, Dekker A, Bitnun S, Waters V, Yau Y, Solomon M, Ratjen F. Clinical Evaluation of Once-Daily Tobramycin Dosing Guidelines In Paediatric Patients with Cystic Fibrosis. *Pediatric Pulmonol* 2007; Suppl 30:356A.
148. Wells GD, Wilkes DL, Schneiderman-Walker J, Elmi M, Tullis E, Ratjen F, Lands L, Coates AL. Reliability And Validity Of The Habitual Activity Estimation Scale (HAES) In Patients with Cystic Fibrosis. *Pediatric Pulmonol* 2007; Suppl 30:439A
149. Wilkes DL, Schneiderman-Walker J, Corey M, Atenafu E, Li Y, Lands LC, Tullis E, Coates AL, Ratjen F. Longterm Effect Of Habitual Physical Activity On Lung Health In Patients With Cystic Fibrosis. *Pediatric Pulmonol* 2007; Suppl 30:440A.
150. Al-Saleh S, Dell S, Grasemann H, Yau Y, Waters V, Martin S, Ratjen F. Is induced sputum more useful than expecterated sputum to identify respiratory pathogens in children with cystic fibrosis? *Eur Resp J* 2007; 30: Suppl.31, E341, p.31s.
151. Corvol H, Boelle PY, Brouard J, Knauer N, Henrion-Caude A, Chadelat K, Flamant C, Charlier C, Boule M, Fauroux B, Vallet C, Feingold J, Ratjen F, Grasemann H, Clement A. Cytokine polymorphisms influence lung disease progression in cystic fibrosis. *J Cystic Fibrosis* 2008; 7: Suppl 2 S3 (10).
152. Eber E, Grasemann H, Thalhammer GH, Widmann R, Ratjen. Safety, tolerability and efficacy of multiple doses of aerosolised Moli 1901 in adolescents and adults with cystic fibrosis. *J Cystic Fibrosis* 2008; 7: Suppl 2 S3 (90).

153. Ratjen F, Stenglein S, Munck A. Inhaled tobramycin nebulizer solution for treatment of early *Pseudomonas aeruginosa* infection: the ELITE study. *J Cystic Fibrosis* 2008; 7: Suppl 2S3 (101).
154. Subbarao P, Balkovec S, Osman M, Keast C, Ratjen F. Effect of repeated raised volume forced expirations on plethysmographic lung volumes in infants. *Am J Respir Crit Care Med* 2008; 117:A56.
155. Subbarao P, Keast C, Balkovec S, Ratjen F. Infant lung function in a cohort of infants after severe wheezing illness. The American Thoracic Society International Conference, Toronto. *Am J Respir Crit Care Med* 2008; 117:A701.
156. Corvol H, Boelle PY, Brouard J, Knauer N, Chadelat K, Henrion-Claude K, Flanant C, Chatlir C, Boule M, Fauroux B, Vallet C, Feingold I, Ratjen F, Grasemann H, Clement A. Genetic Variation in Inflammatory Mediators Influence Lung Disease Progression in Cystic Fibrosis. *Am J Respir Crit Care Med* 2008; 117:A459.
157. Grasemann H, Al-Saleh S, Shehnez D, Ratjen F. Sputum Arginase Activity in Relation to Pathogens and Inflammation in the Lower Airways of Stable Children with Cystic Fibrosis. *Am J Respir Crit Care Med* 2008; 117:A460.
158. Amin R, Corey M, Aaron SD, Tullus E, Ratjen F. Chronic Infection with *Aspergillus fumigatus* Is Associated with Higher Rates of Pulmonary Exacerbations in Cystic Fibrosis Patients. *Am J Respir Crit Care Med* 2008; 117:A460.
159. Al-Saleh S, Letarte M, Mei-Zahav M, Carpetner S, Ratjen F. Screening for Arterious Malformations in Children with Hereditary Hemorrhagic Telangiectasis. *Am J Respir Crit Care Med* 2008; 117:A699.
160. Subbarao P, Keast C, Balkovec S, Ratjen F. Infant lung function in a cohort of infants after severe wheezing illness. *Am J Respir Crit Care Med* 2008; 117:A701
161. Mateos-Corral D, Coombs R, Grasemann H, Ratjen F, Dell SD. How Should nasal Nitric Oxide Be Measured To Screen for PCD in Children? *Am J Respir Crit Care Med* 2008; 117:A798.
162. Bhattacharjee R, Wells GD, Wilkes DL, Al-Saleh S, Silverman E, Grasemann H, Selvadurai H, Ratjen F, Coates AL. Inhaled Nitric Oxide and Ventilation Distribution in Children with Lupus. *Am J Respir Crit Care Med* 2008; 117:A885.
163. Grasemann H, Al-Saleh S, Shehnaz D, Ratjen F. Factors Influencing Sputum Arginase Activity in Children with Cystic Fibrosis in Stable Disease and During Treatment of Pulmonary Exacerbation. *Pediatric Pulmonol* 2008; Suppl 31:154A.
164. Corvol H, Buelle P, Brouard J, Flamant C, Charlier C, Boule M, Fauroux B, Valet C, Feingold I, Ratjen F, Grasemann H, Clement A. *TGFBI* Gene is An Important Genetic Modifier in Children with Cystic Fibrosis. *Pediatric Pulmonol* 2008; Suppl 31:213A.
165. Ratjen F, Munck A, Kho P. Short and Long-Term Efficacy of Inhaled Tobramycin in Early *P. aeruginosa* Infection: The Elite Study. *Pediatric Pulmonol* 2008; Suppl 31:334A.
166. Prasad S, Yau Y, Crandall I, Tom S, Ratjen F, Hoiby N, tullis E, Corey M, Waters V. Development of a Serologic Assay To Detect Antibodies To *S. maltophilia* in Cystic Fibrosis

Patients. *Pediatric Pulmonol* 2008; Suppl 31:389A.

167. Tjon JA, Chan C, Murphy L, Seto W, Atenafu E, Wong C, Dekker A, Bitnun A, Waters V, Yau Y, Solomon M, Ratjen F. Clinical Evaluation of Once-Daily Dosing tobramycin Guidelines in Paediatric Patients with Cystic Fibrosis. *Pediatric Pulmonol* 2008; Suppl 31:426A.
168. Amin R, Dupuis A, Aaron S, Tullis E, Ratjen F. The Effect of Chronic Infection with *Aspergillus Fumigatus* on Pulmonary Exacerbations and Forced Expiratory Volume in One Second in Pediatric Cystic Fibrosis Patients. *Pediatric Pulmonol* 2008; Suppl 31:403A.
169. Leahy TR, Yau Y, Ratjen F, Corey M, Waters V. MRSA in a Pediatric CF Clinic Population: Clinical and Molecular Epidemiology Risk Factors for Colonization, and Impact on Disease Progression. *Pediatric Pulmonol* 2008; Suppl 31:434A.
170. Rosenfeld M, Davis S, Brumback L, Daniel S, Johnson R, Rowbotham R, McNamara A, Martin S, Barlow C, Ratjen F. Inhaled 7% Hypertonic Saline is Well tolerated in Infants and Toddlers with CF. *Pediatric Pulmonol* 2008; Suppl 31:444A.
171. Wilkes DL, Schneiderman-Walker J, Atenafu E, Wells G, Tullis E, Lands L, Corey M, Coates AL, Ratjen F. Bone Mineral Density and Habitual Physical Activity in Cystic Fibrosis. *Pediatric Pulmonol* 2008; Suppl 31:647A.
172. Amin R, Dompeling E, Keast C, Balkovec S, Shehnaz D, Rijkers GT, Al-Saleh S, Ratjen F, Grasemann H, Subbarao P. Non-Invasive Assessment of Airways Inflammation in Pediatric Asthma. *Am. J. Respir. Crit. Care Med.*, 2009; 179: A1383.
173. Amin R, Charron M, Ratjen F. A Pilot Study of <sup>18</sup>F-DG-PET Imaging To Detect Changes in Airways Inflammation in Pediatric Cystic Fibrosis Patients after Treatment for a Pulmonary Exacerbation. *Am. J. Respir. Crit. Care Med.*, 2009; 179: A5371

#### **D. PRESENTATIONS AND SPECIAL LECTURES**

Papers presented at meetings and symposia (list dates, locations)

1. Normal findings for BAL in children. International congress for pediatric pulmonology. 3. 6.1996, Nizza.
2. How do I treat this patient? European CF conference, 17.6.1997, Davos.
3. Role of bronchoalveolar Lavage. German CF meeting. 1. 11 1997, Lahnstein.
4. Evaluation of airway inflammation in CF, the BEAT projekt. CF-meeting, 15.11.1997, Hanover.
5. Immunology of the newborn lung. German Society for Pediatric Pulmonology, 3.4.1998, Freiburg.
6. Early antibiotic therapy in cystic fibrosis. 22nd European CF Conference. 17. 6.1998, Berlin.
7. Eradication of *Pseudomonas aeruginosa* by early antibiotic treatment. 22<sup>nd</sup> European CF conference, 17.6.1998, Berlin.

8. Cystic fibrosis. 24 Pulmonology Meeting: Inherited diseases of the lung. 21.10.1998, Ruhrlandklinik, Essen
9. Early antibiotic treatment: The german approach. National Symposium on Cystic Fibrosis. 19.11.1998, Leuven.
10. BAL indications and methodology. German Society for pediatric pulmonology,, 18.3.1999, Salzburg.
11. Cystic fibrosis. Regimens for antibiotic treatment. European Society of Chemotherapy, 20.5.1999, Istanbul.
12. Bronchoalveolar Lavage. Processing of specimens. European Society of Pediatric Allergy and Clinical Immunology. 27.5.1999, Berlin.
13. Bronchoalveolar lavage in children: Reference values. European Respiratory Society, 18.9.1999, Madrid.
14. Changes in optimal antibiotic treatment in cystic fibrosis. BICON 14.3.2000,. München.
15. Role of BAL in cystic fibrosis. 7<sup>th</sup> International conference on BAL, 29.6.2000, Krakau.
16. BAL in children with allergic alveolitis. 7<sup>th</sup> International conference on BAL, 29.6.2000, Krakau.
17. Update on microbiology in CF. German Society for pediatric infectious diseases. 5.10.2000; Dresden.
18. Evaluation of airway inflammation in cystic fibrosis. Emma Thaler Symposium. 21.10.2000, München.
19. Mieux définir l'inflammation et l'infection dans le moins de trois ans. French CF meeting. 5.12.2000, Paris.
20. Anti-inflammatory therapy in CF. German Society for pediatric pulmonology,. 15.3.2001, Bern.
21. Diagnostic role of BAL. German Society for Pediatric Pulmonology,. 15.3.2001, Bern.
22. Techniques for measuring NO in children. German Society for Pulmonology, 21.3.2001, Jena.
23. Strategies of antibiotic therapy in CF. Northern German Conference for Chemotherapy. 5.5.2001, Boltenhagen
24. Inflammatory processes in the lung. German Pediatric Society,. 14.9.2001, Freiburg.
25. Highlights of CF research 2001. German CF meeting, 18.10.2001, Fulda.
26. Paediatric bronchoscopy. CIPP Congress, International Congress for Pediatric Pulmonology. 18.2.2002, Nizza

27. Airway inflammation in cystic fibrosis. . International congress for Pediatric Pulmonology. 21.2.2002, Nizza
28. Clinical assessment of airway inflammation. European Cystic Fibrosis Conference. 21.6.2002, Genoa.
29. Diagnosis of infection in infants. European Cystic Fibrosis Conference. 22.6.2002, Genoa.
30. Update for paediatric bronchoscopy. European Respiratory Society, 18.9.2002; Stockholm.
31. Techniques to define airway inflammation in CF. Swiss CF Meeting, 2.10.2002, Bern
32. Early therapy for pseudomonas infection in CF. German Society for pediatric infectious diseases, 5.10.2002; Wiesbaden.
33. Eradication of Pseudomonas by inhalation with tobramycin. The Children's Hospital, 15.10.2002, Boston.
34. Role of BAL in paediatric lung diseases. Pediatric Pulmonology meeting, Mass. General Hospital, 17.10. 2002, Boston.
35. Early intervention in CF. German Society for Pediatric Pulmonology,, 25.4.2003, Wien.
36. Airway inflammation in CF-an overview. European Cystic Fibrosis Conference, 7.6.2003; Belfast.
37. Early antibiotic therapy for P. aeruginosa. European Cystic Fibrosis Conference, 8.6.2003; Belfast.
38. There is sufficient evidence to advocate early intervention for P. aeruginosa infection: Pro. North American CF conference, 16.10.2003, Anaheim.
39. Diagnosis and management of Pseudomonas aeruginosa infection- from first isolation to chronic infection. European Respiratory Society, 27.9.2004; Vienna.
40. Ontario CF Meeting, Toronto, Ontario, Apr 15, 2005. Early Intervention for Pseudomonas.
41. Early intervention/eradication. 28th European Cystic Fibrosis Conference - Crete, Greece, Jun 22- 25, 2005.
42. Airway Inflammation. 6th Australian & NZ CF Conference, Adelaide, Australia, August 20-23, 2005.
43. Early Intervention is the Key. 6th Australian & NZ CF Conference, Adelaide, Australia, August 20-23, 2005.
44. Keynote Address. 6th Australian & NZ CF Conference, Adelaide, Australia, August 20-23, 2005.

45. Early intervention/eradication. Children's Hospital at Westmead, Sydney, Australia. August 24, 2005.
46. Airway inflammation. Royal Children's Hospital, Melbourne, Australia, August 25, 2005.
47. Clinical Progress on Many Fronts: Evaluating New CF Therapies. 19th Annual North American CF Conference - Baltimore, Maryland, USA, Oct 21-23, 2005.
48. New Asthma Guidelines and New Happenings in Respiriology. 7<sup>th</sup> Annual William Osler Health Centre, Paediatric Clinic Day, Toronto, October 29, 2005.
49. Early intervention – The balance value, is it a risk worth taking? UK National Cystic Fibrosis Meeting – Nov 13-14, 2005
50. Role of Nitric Oxide and PCD. Neonatology Rounds, Mt. Sinai Hospital, Toronto, December 22, 2005.
51. Clinical Research Related to CF Lung Disease. Research-in-Progress, Lung Biology, Research Institute, Sick Kids Hospital, January 30, 2006
52. Pediatric Grand Rounds: Advances in Understanding and Treating Airways Disease in Cystic Fibrosis. Alberta Children's Hospital, University of Alberta, Calgary, Alberta, March 01, 2006.
53. Strategies to enhance airway clearance with reference to the hypertonic study. CF Journal Club, Alberta Children's Hospital, University of Alberta, Calgary, Alberta, March 01, 2006.
54. Role of Nitric Oxide in Asthma and CF. Respiratory Rounds. Alberta Children's Hospital, University of Alberta, Calgary, Alberta, March 02, 2006.
55. BAL. Fellow Rounds. Alberta Children's Hospital, University of Alberta, Calgary, Alberta March 02, 2006.
56. Chloride activation, NO augmentation and P. aeruginosa eradication: Approaches to improve outcome in CF. CF Research Seminar, Sick Kids Hospital, March 20, 2006.
57. Early intervention strategies in CF. Arkon Children's Hospital, Cleveland. April 05, 2006.
58. Airway inflammation – results of BEAT study. Rainbow Babies Hospital, Cleveland, April 05, 2006.
59. Airway inflammation in CF. Medical College of Wisconsin, Milwaukee. April 06. 2006.
60. Grand Rounds: Early intervention in pediatric lung diseases. Medical College of Wisconsin, Milwaukee. April 07, 2006.
61. Grand Rounds: Asthma. North York General Hospital, Toronto. May 01, 2006.
62. Airway clearance techniques. Ontario CF Meeting, May 13, 2006.
63. CF Infection. CF Provincial Day, Sherbrooke May 26, 2006

64. Antibody measurements for monitoring early eradication therapy. 29<sup>th</sup> European Cystic Fibrosis Conference, Copenhagen, Denmark, June 15-18, 2006.
65. Role of DNase in reducing pulmonary inflammation. 29<sup>th</sup> European Cystic Fibrosis Conference, Copenhagen, Denmark, June 15-18, 2006.
66. Place of inhaled antibiotics in cystic fibrosis care. 29<sup>th</sup> European Cystic Fibrosis Conference, Copenhagen, Denmark, June 15-18, 2006.
67. Diagnosing and Managing Infection. 7th International Congress on Pediatric Pulmonology July 8-11, 2006, Montreal, Quebec, Canada, Jul 8 -11, 2006.
68. Airway Inflammation in Pediatric Lung Disease. Respirology Resident Seminar Series 2006-7, University of Toronto, Sep 27, 2006.
69. Treatment and Prevention of Early *P. aeruginosa* Infection. Short Course #1: Drug Treatment Options: Beyond the Basics. North American Cystic Fibrosis Conference, Denver, November 2-5, 2006.
70. Multi-center, double-blind RCT evaluating the metabolic and respiratory effects of growth hormone in CF Workshop #5: Endocrine & Bone Health. North American Cystic Fibrosis Conference, Denver, November 2-5, 2006.
71. Safety and efficacy of aerosolised Moli1901 in patients with cystic fibrosis. Workshop #6: New Clinical Therapies. North American Cystic Fibrosis Conference, Denver, November 2-5, 2006.
72. Inhaled TNS for early *Pseudomonas aeruginosa* infection: ELITE study interim results. Workshop#24: New Strategies for Treating Airway Infection. North American Cystic Fibrosis Conference, Denver, November 2-5, 2006.
73. CF and Exercise. Canadian Cystic Fibrosis Foundation Ontario Provincial Association Meeting, Toronto, November 10, 2006.
74. Consistent therapy from the outset: ELITE. Cystic Fibrosis Conference, Würzburg, Germany, November 16, 2006.
75. Managed care for cystic fibrosis. AGAM Further Training Day. Cystic Fibrosis Conference, Würzburg, Germany, November 16, 2006.
76. The role of nitric oxide in CF lung disease. The Cotton Club - Denver Children's - Pediatric Pulmonary Section, Breckenridge, Colorado – February 22-24, 2007.
77. Early Intervention Strategies in CF. The Cotton Club - Denver Children's - Pediatric Pulmonary Section, Breckenridge, Colorado – February 22-24, 2007.
78. How to Assess Clinical Efficacy of Therapeutic Interventions in Cystic Fibrosis. CF Research Seminar – The Hospital for Sick Children, March 26, 2007.
79. *P. aeruginosa* early eradication trials, the role of inhaled tobramycin and the future of antibiotic therapy in CF. National Consultant Meeting: Clinical Developments in Cystic Fibrosis, Toronto, June 1, 2007.

80. Early Infection – host response. Cystic Fibrosis Foundation, Williamsburg Conference June 1-5, 2007.
81. Mucus composition in CF – impact of inflammation. Symposium: Exploring the link between sputum and clinical response: focus on dornae alfa. 30<sup>th</sup> ECFS Conference, Belek, Turkey, June 15, 2007
82. Clinical Trails in CF: an international perspective. 2007 Broken Arrow Conference, Orford, Quebec, Sep.05-07, 2007
- 83.** CF lung disease: from molecular defect to abnormal mucociliary clearance” Paediatric respiratory medicine: cystic fibrosis – the basics. Postgraduate Course ERS Stockholm 2007 Congress, September 15, 2007.
84. CF Drug Developments: What’s New? Plenary Session, 2007 North American CF Conference, Anaheim, CA Oct. 3-6, 2007.
85. Pneumonias from infancy through adolescence, Annual William Osler Clinic Day , Toronto, Nov 03, 2007.
86. Grand Rounds: Early Intervention Strategies in Cystic Fibrosis. Visiting Professorship, St. Christopher’s Hospital, Philadelphia Nov 09, 2007
87. Cystic fibrosis: airways inflammation. VII Latin-American Congress of Pediatric Pulmonology & XII Latin-American Congress of Cystic Fibrosis, Mar del Plata, Argentina, Nov. 14-17, 2007.
88. Early intervention in CF. VII Latin-American Congress of Pediatric Pulmonology & XII Latin-American Congress of Cystic Fibrosis, Mar del Plata, Argentina, Nov. 14-17, 2007.
89. Treatment of infections in CF. VII Latin-American Congress of Pediatric Pulmonology & XII Latin-American Congress of Cystic Fibrosis, Mar del Plata, Argentina, Nov. 14-17, 2007.
90. Airway clearance in CF patients. VII Latin-American Congress of Pediatric Pulmonology & XII Latin-American Congress of Cystic Fibrosis, Mar del Plata, Argentina, Nov. 14-17, 2007.
91. New therapies in cystic fibrosis: How basic science is driving clinical developments. Research Institute Retreat, November 26, 2007
92. New approaches to treat CF lung disease? Research in Progress, Respirology Division, University of Toronto, Dec 05, 2007.
93. Treatment of early P. aeruginosa infection. St.Louis CF team. St. Louis. December 12<sup>th</sup> , 2007
94. Treatment of early P. aeruginosa infection. John Hopkin’s CF team. Baltimore. January 23<sup>th</sup> , 2008
95. P. aeruginosa antibodies: State of the Art. CFF Workshop. Bethesda January 30<sup>th</sup>, 2008. aeruginosa antibodies

96. Growth and puberty in cystic fibrosis: endocrinology and pulmonology interaction. Controversial Issues in Pediatric Endocrinology. Royal College of Obstetricians and Gynaecologists, London, UK, Feb. 01, 2008,
97. TIGER 2: What will we learn? TIGER investigator meeting. Cancun. February 2<sup>nd</sup>, 2008.
98. HHT – Childhood presentations of an adult disease. IGT Lecture Series, The Hospital for Sick Children, Feb. 29, 2008
99. Hereditary Diseases of the Respiratory System. Current Topics in Medical Genetics Course, The Hospital for Sick Children. Mar 13, 2008
100. Cystic fibrosis: Diagnostic challenges of newborn screening. DPLM Rounds, The Hospital for Sick Children. Apr.24, 2008.
101. New evidence in early eradication of *P. aeruginosa* in CF patients. Hamilton CF Group, Burlington, ON July 23, 2008.
102. Recent advances in treating CF lung disease. The Thirtieth Stephanie Lynn Kossoff Memorial Lecture, The Department of Pediatrics, College of Physicians & Surgeons of Columbia University and Morgan Stanley Children's Hospital of New York, Sep 19, 2008
103. New pulmonary therapies for cystic fibrosis. 4<sup>th</sup> Chilean Congress of Pediatric Pulmonology, Santiago, Chile, Oct.15-18, 2008.
104. Growth hormone in children with cystic fibrosis. 4<sup>th</sup> Chilean Congress of Pediatric Pulmonology, Santiago, Chile, Oct.15-18, 2008.
105. What's new in CF airway inflammation. 4<sup>th</sup> Chilean Congress of Pediatric Pulmonology, Santiago, Chile, Oct.15-18, 2008.
106. Recent advances in treating CF lung disease. The Thirtieth Stephanie Lynn Kossoff Memorial Lecture, The Department of Pediatrics, College of Physicians & Surgeons of Columbia University and Morgan Stanley Children's Hospital of New York, Sep 19, 2008.
107. Are clinical signs and symptoms a starting point or a mid-point in lung disease? South Florida Consortium of Pediatric Pulmonology. Ft Lauderdale, Florida, Oct.19, 2008
108. Grand Rounds – “Pediatric Bronchoscopy” University of Miami, October 20, 2008.
109. Infection in CF: early detection. Update on Pulmonary Disease. 14<sup>th</sup> Italian Cystic Fibrosis Congress. Turin, Italy Nov 27-29, 2008.
110. Early childhood origins of asthma: what do we still need to know?. The Gerry Schwartz and Heather Reisman, 2nd International Congress on Chronic Disorders & Disabilities in Children. Jerusalem, Israel, Dec 3 – 4, 2008.
111. Inhalation therapy in CF. National Cystic Fibrosis Conference, Jerusalem, Israel, Dec. 5, 2008.
112. Chronic Lung Disease as a Differential Diagnosis of Cystic Fibrosis. M Soto-Quiros Pediatric Meeting Costa Rica, Mar 25, 2009.

113. New Therapies and Hopes for Cystic Fibrosis in Children. M Soto-Quiros Pediatric Meeting Costa Rica, Mar 25, 2009.
114. Grand Rounds – “Mastering HHT: An Opportunity for Prevention”. The Hospital for Sick Children, Apr 22, 2009

#### **VIDEOS/MOVIES PRODUCED**

1. Webconference Series – Topic: "Improving Airway Clearance in CF". Jun 19 – Jul 14, 2006.
2. ERS Online Course on Paediatric Respiratory Medicine – Topic: “CF - How basic science is driving the search for new treatments?” May 03, 2007.
3. Treatment of P. aeruginosa Infection – When and How. July 2007
4. CFF Webcast: “CF Drug Development: What’s New?” – Nov 20, 2007

#### **E. TEACHING AND DESIGN**

##### TEACHING Undergraduate

##### Graduate

- |             |   |
|-------------|---|
| 1996-3.2005 | Pediatric Pulmonology, University of Essen  |
| 1993-3.2005 | Bed side courses in pediatrics  |
| 1996-3.2005 | Tutorial courses for graduate students  |
| 1997-3.2005 | Chief instructor for students at the Children’s Hospital, University of Essen   |
| 2007        | Respiratory Physiology Course #PSL 1069H - Session #4<br>Lung Defenses - Applied - immunodeficiency, cystic fibrosis, ciliary dysmotility, transplantation, gene therapy...<br><i>Student-led seminar - 2 hours</i> – Felix Ratjen (Seminar Leader) - Feb. 01, 2007 |

##### Postgraduate

- |             |  |
|-------------|--|
| 1999-3.2005 | ERS hands on course of paediatric bronchoscopy in Lille; France  |
| 2006        | Hands on bronchoscopy course. Pediatric Respiratory Medicine Fellows. Mt. Sinai Hospital April 24, 2006.<br><br>Pediatric Respiratory Medicine Fellows – Dec. 20, 2006<br><br>Pediatric Respiratory Medicine Fellows<br>Mar19, 2007 Congenital Malformations of the Lung |

Apr. 18, 2007 Pulmonary Therapies and Cystic Fibrosis  
 May 04, 2007 Hypertonic Saline and Azithromycin  
 May 18, 2007 Assessing Response to Treatment.  
 May 25, 2007 Exercise Exacerbation in CF.  
 Dec 06, 2007 X-ray Rounds  
 Oct 03, 2007 Short Course: Drug Options in CF Care: Beyond the Basics, North American CF Conference, Anaheim, CA Oct 3-6  
 Nov 09, 2007 Grand Rounds: Early Intervention Strategies In Cystic Fibrosis. Visiting Professorship, St. Christopher's Hospital, Philadelphia  
 2008 Clinical Genetics trainees academic half day - Current Topics in Medical Genetics Course - Hereditary Diseases of the Respiratory System – Mar 13, 2008

**F. GRADUATE STUDENT THESIS SUPERVISION**

1. Indicate whether primary or secondary supervisor.
2. Master and Doctoral Students: name, theses, topic, dates, including period of supervision.
3. Postdoctoral Fellows: name, topic, dates.

1997- 2000	Student: Degree: Title:	Eveline Michler (University of Essen) PhD equivalent Nitric oxide in exhaled air of patients with cystic fibrosis.
1998- 2001	Student: Degree: Title:	Ilka Kavuc (University of Essen) PhD equivalent Measurements of nasal and expiratory nitric oxide in infants with obstructive airway bronchitis.
1999- 2002	Student: Degree: Title:	Sebastian Gärtig (University of Essen) PhD equivalent Effect of L-arginine infusion on nitric oxide formation in the lower and upper airways of patients with cystic fibrosis or primary ciliary dyskinesia.
2001- 2004	Student: Degree: Title:	Nicola Knauer (University of Essen) PhD equivalent The role of variants in the neuronal nitric oxide synthase (NOS1) gene for NO formation and bacterial colonization of airways in cystic fibrosis patients.
2001- 2006	Student: Degree: Title:	Dr. Samira Hischma (University of Essen) PhD equivalent Methodological aspects of NO measurements in infants.

2002-	Student: Degree: Title:	Nadine Schwendmann (University of Essen) PhD equivalent Cystic fibrosis modifier genes in children: the role of ACE.
2002-	Student: Degree: Title:	Elke Reutershan (University of Essen) PhD equivalent Effect of growth hormone therapy on NO metabolism in CF patients.
2003-	Student: Degree: Title:	Fionn Kuntz (University of Essen) PhD equivalent Effect of inhaled L-arginine on exhaled NO and pulmonary function in patients with CF.
2003-	Student: Degree: Title:	Raphael Schwiertz (University of Essen) PhD equivalent The role of arginase in CF airway inflammation and obstruction.
2003- 2006	Student: Degree:	Dr. Joanna MacLean Postdoctoral Fellowship
2004-	Student: Degree:	Dr. Anwar Sallam Postdoctoral Fellowship
2004- 2007	Student: Degree:	Dr. Suhail Al-Saleh Postdoctoral Fellowship
2004- 2006	Student: Degree:	Dr. Tauyee Hsieh Postdoctoral Fellowship
2005- 2007	Student: Degree:	Dr. Dhenuka Radhakrishnan Postdoctoral Fellowship
2005- 2007	Student: Degree:	Dr. Reshma Amin Postdoctoral Fellowship
2005- 2007	Student: Degree:	Dr. Rakesh Bhattacharjee Postdoctoral Fellowship
2006- 2008	Student: Degree:	Dr. Dimas Mateos-Corral Postdoctoral Fellowship
2006- 2008	Student: Degree:	Dr. Harutai Kamalaporn Postdoctoral Fellowship
2006- 2008	Student: Degree:	Dr. Mustafa Osman Postdoctoral Fellowship
2007- 2008	Student: Degree:	Dr. Sintra Phumethum Postdoctoral Fellowship (one year)
2007- 2009	Student: Degree:	Dr. Tara Renee Allen Postdoctoral Fellowship

2007-2009 Student: Dr. Tania Samantha  
Degree: Postdoctoral Fellowship

2007-2009 Student: Dr. Joanna Lesley Swinburne  
Degree: Postdoctoral Fellowship

2007-2009 Student: Dr. Suhail Al-Saleh  
Degree: Postdoctoral Fellowship in Sleep Medicine

### **Graduate Student**

#### **Co-Supervisor**

2007-2009 Student: Dr. Reshma Amin  
Degree: Masters in Epidemiology  
Topic: 1. Positron Emission Tomography (PET) as a Marker of Airways Inflammation in patients with Cystic Fibrosis (CF)  
2. The effect of hypertonic saline on the Lung Clearance Index in patients with Cystic Fibrosis

### **PhD Committee**

Firhan A. Malik PhD. Candidate (Department of Physiology)  
Project: The role of S1P-signalling and AMPK in the functional expression of the CysticFibrosis Transmembrane Conductance Regulator Protein  
Supervisor: Dr. St-S. Bolz  
Committee Members: Dr. C.E. Bear, Dr. P. Brubaker, and Dr. F. Ratjen

Last modified: 2009-12-18